Alphatec (ATEC) 10-K 20 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 19, 2014	Jun. 28, 2013
Entity Information [Line Items]	'	'	'
Entity Registrant Name	'Alphatec Holdings, Inc.	'	'
Entity Central Index Key	'0001350653	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Document Type	'10-K	'	'
Trading Symbol	'ATEC	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Amendment Flag	'false	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Common Stock, Shares Outstanding	'	97,600,388	'
Entity Public Float	'	'	$126.50

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash	$21,345	$22,241
Accounts receivable, net	41,395	41,012
Inventories, net	41,939	49,855
Prepaid expenses and other current assets	7,694	5,953
Deferred income tax assets	1,372	2,991
Total current assets	113,745	122,052
Property and equipment, net	28,030	30,403
Goodwill	183,004	180,838
Intangibles, net	39,064	46,856
Other assets	1,787	1,978
Total assets	365,630	382,127
Current liabilities:	'	'
Accounts payable	10,790	15,237
Accrued expenses	62,996	38,490
Deferred revenue	1,009	1,361
Current portion of long-term debt	4,924	1,700
Total current liabilities	79,719	56,788
Long-term debt, less current portion	49,978	39,967
Other long-term liabilities	38,784	13,485
Deferred income tax liabilities	1,870	2,468
Commitments and contingencies	'	'
Redeemable preferred stock, $0.0001 par value; 20,000 authorized at December 31, 2013 and 2012; 3,319 shares issued and outstanding at both December 31, 2013 and 2012	23,603	23,603
Stockholders’ equity:	'	'
Common stock, $0.0001 par value; 200,000 authorized; 97,599 and 96,703 shares issued and outstanding at December 31, 2013 and 2012, respectively	10	10
Treasury stock, 19 shares	-97	-97
Additional paid-in capital	403,568	399,246
Accumulated other comprehensive income (loss)	3,877	112
Accumulated deficit	-235,682	-153,455
Total stockholders’ equity	171,676	245,816
Total liabilities and stockholders’ equity	$365,630	$382,127

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Redeemable preferred stock, par value	$0.00	$0.00
Redeemable preferred stock, shares authorized	20,000,000	20,000,000
Redeemable preferred stock, shares issued	3,319,000	3,319,000
Redeemable preferred stock, shares outstanding	3,319,000	3,319,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	97,599,000	96,703,000
Common stock, shares outstanding	97,599,000	96,703,000
Treasury stock, shares	19,000	19,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Revenues	$204,724	$196,278	$197,711
Cost of revenues	78,669	70,761	79,168
Amortization of acquired intangible assets	1,733	1,749	1,613
Gross profit	124,322	123,768	116,930
Operating expenses:	'	'	'
Research and development	14,190	14,886	16,888
In-process research and development	0	341	0
Sales and marketing	76,960	75,177	75,189
General and administrative	47,949	39,939	36,367
Amortization of acquired intangible assets	3,009	2,180	2,152
Transaction related expenses	0	1,082	0
Restructuring expenses	9,665	0	1,050
Litigation settlement expenses	45,982	0	9,800
Total operating expenses	197,755	133,605	141,446
Operating loss	-73,433	-9,837	-24,516
Other income (expense):	'	'	'
Interest income	6	118	148
Interest expense	-3,959	-6,105	-3,027
Other income (expense), net	-1,662	-794	707
Total other income (expense)	-5,615	-6,781	-2,172
Pretax net loss	-79,048	-16,618	-26,688
Income tax provision (benefit)	3,179	-1,159	-4,507
Net loss	($82,227)	($15,459)	($22,181)
Net loss per common share:	'	'	'
Basic and diluted (in dollars per share)	($0.85)	($0.17)	($0.25)
Weighted-average shares used in computing net loss per share:	'	'	'
Basic and diluted (in shares)	96,235	90,218	88,798

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Net loss	($82,227)	($15,459)	($22,181)
Foreign currency translation adjustments	3,765	2,924	-1,502
Comprehensive loss	($78,462)	($12,535)	($23,683)

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Phygen, LLC [Member]	Common stock [Member]	Common stock [Member]	Additional paid-in capital [Member]	Additional paid-in capital [Member]	Treasury Stock [Member]	Accumulated other comprehensive income (loss) [Member]	Accumulated deficit [Member]
In Thousands, except Share data, unless otherwise specified				Phygen, LLC [Member]		Phygen, LLC [Member]
Balance beginning, value at Dec. 31, 2010	$266,434	'	$9	'	$383,647	'	($97)	($1,310)	($115,815)
Balance beginning, shares at Dec. 31, 2010	'	'	89,040,000	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Stock-based compensation	2,525	'	'	'	2,525	'	'	'	'
Exercise of stock options, value	104	'	'	'	104	'	'	'	'
Exercise of stock options, shares	'	'	55,000	'	'	'	'	'	'
Repurchase and/or forfeiture of common stock, value	-193	'	'	'	-193	'	'	'	'
Repurchase and/or forfeiture of common stock, shares	'	'	-67,000	'	'	'	'	'	'
Mark-to-market for third party restricted stock	-100	'	'	'	-100	'	'	'	'
Issuance of warrants in connection with credit facility	99	'	'	'	99	'	'	'	'
Issuance of common stock for employee stock purchase plan, value	142	'	'	'	142	'	'	'	'
Issuance of common stock for employee stock purchase plan, shares	'	'	63,000	'	'	'	'	'	'
Issuance of common stock for restricted share awards granted to employees, value	0	'	'	'	'	'	'	'	'
Issuance of common stock for restricted share awards granted to employees, shares	'	'	271,000	'	'	'	'	'	'
Foreign currency translation adjustments	-1,502	'	'	'	'	'	'	-1,502	'
Net loss	-22,181	'	'	'	'	'	'	'	-22,181
Balance ending, value at Dec. 31, 2011	245,328	'	9	'	386,224	'	-97	-2,812	-137,996
Balance ending, shares at Dec. 31, 2011	'	'	89,362,000	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Stock-based compensation	2,406	'	'	'	2,406	'	'	'	'
Exercise of stock options, value	76	'	'	'	76	'	'	'	'
Exercise of stock options, shares	'	'	62,000	'	'	'	'	'	'
Repurchase and/or forfeiture of common stock, value	-49	'	'	'	-49	'	'	'	'
Repurchase and/or forfeiture of common stock, shares	'	'	-115,000	'	'	'	'	'	'
Issuance of common stock for employee stock purchase plan, value	200	'	'	'	200	'	'	'	'
Issuance of common stock for employee stock purchase plan, shares	'	'	145,000	'	'	'	'	'	'
Issuance of common stock for restricted share awards granted to employees, value	0	'	'	'	'	'	'	'	'
Issuance of common stock for restricted share awards granted to employees, shares	'	'	701,000	'	'	'	'	'	'
Shares issued for consulting services, value	1,284	'	'	'	1,284	'	'	'	'
Shares issued for consulting services, shares	'	'	938,000	'	'	'	'	'	'
Issuance of common stock in connection with license agreements, value	250	'	'	'	250	'	'	'	'
Issuance of common stock in connection with license agreements, shares	'	'	139,000	'	'	'	'	'	'
Issuance of common stock in connection with acquisition, value	'	8,856	'	1	'	8,855	'	'	'
Issuance of common stock in connection with acquisition, shares	'	'	'	5,240,000	'	'	'	'	'
Issuance of common stock for equity offering, shares	'	'	231,000	'	'	'	'	'	'
Foreign currency translation adjustments	2,924	'	'	'	'	'	'	2,924	'
Net loss	-15,459	'	'	'	'	'	'	'	-15,459
Balance ending, value at Dec. 31, 2012	245,816	'	10	'	399,246	'	-97	112	-153,455
Balance ending, shares at Dec. 31, 2012	'	'	96,703,000	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Stock-based compensation	2,590	'	'	'	2,590	'	'	'	'
Exercise of stock options, value	8	'	'	'	8	'	'	'	'
Exercise of stock options, shares	6,000	'	6,000	'	'	'	'	'	'
Repurchase and/or forfeiture of common stock, value	-172	'	'	'	-172	'	'	'	'
Repurchase and/or forfeiture of common stock, shares	'	'	-142,000	'	'	'	'	'	'
Issuance of common stock for employee stock purchase plan, value	719	'	'	'	719	'	'	'	'
Issuance of common stock for employee stock purchase plan, shares	'	'	500,000	'	'	'	'	'	'
Issuance of common stock for restricted share awards granted to employees, value	0	'	'	'	'	'	'	'	'
Issuance of common stock for restricted share awards granted to employees, shares	'	'	376,000	'	'	'	'	'	'
Shares issued for consulting services, value	1,488	'	'	'	1,488	'	'	'	'
Shares issued for consulting services, shares	'	'	354,000	'	'	'	'	'	'
Issuance of common stock in connection with license agreements, value	250	'	'	'	250	'	'	'	'
Issuance of common stock in connection with license agreements, shares	'	'	130,000	'	'	'	'	'	'
Forfeiture of common stock in connection with acquisition, value	'	-561	'	'	'	-561	'	'	'
Forfeiture of common stock in connection with acquisition, shares	'	'	'	-328,000	'	'	'	'	'
Foreign currency translation adjustments	3,765	'	'	'	'	'	'	3,765	'
Net loss	-82,227	'	'	'	'	'	'	'	'
Balance ending, value at Dec. 31, 2013	$171,676	'	$10	'	$403,568	'	($97)	$3,877	($235,682)
Balance ending, shares at Dec. 31, 2013	'	'	97,599,000	'	'	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities:	'	'	'
Net loss	($82,227)	($15,459)	($22,181)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'	'
Depreciation and amortization	26,277	23,792	19,876
Stock-based compensation	4,078	3,690	2,425
Interest expense related to amortization of debt discount and debt issuance costs	368	919	375
In-process research and development	0	341	0
Provision for doubtful accounts	404	859	1,094
Provision for excess and obsolete inventory	11,652	6,658	4,564
Litigation settlement	0	0	9,800
Deferred income tax provision (benefit)	816	-3,420	-4,345
Other non-cash items	1,464	2,158	0
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-1,940	382	-5,004
Inventories	-4,407	-7,853	1,084
Prepaid expenses and other current assets	450	1,681	1,341
Other assets	64	992	1,216
Accounts payable	-3,853	-1,799	2,545
Accrued expenses and other	55,171	-1,764	1,246
Deferred revenue	-510	416	-628
Net cash provided by operating activities	7,807	11,593	13,408
Investing activities:	'	'	'
Purchases of property and equipment	-14,352	-15,646	-8,206
Purchase of intangible assets	-750	-1,750	-690
Cash paid for acquisitions	-4,000	-2,000	-620
Net cash used in investing activities	-19,102	-19,396	-9,516
Financing activities:	'	'	'
Exercise of stock options	8	76	104
Borrowings under lines of credit	154,622	121,232	2,350
Repayments under lines of credit	-168,855	-99,853	-17,346
Principal payments on capital lease obligations	-434	-604	-143
Proceeds from issuance of notes payable	28,000	0	10,000
Principal payments on notes payable	-2,654	-12,375	-1,880
Net cash provided by (used in) financing activities	10,687	8,476	-6,915
Effect of exchange rate changes on cash	-288	902	521
Net increase (decrease) in cash	-896	1,575	-2,502
Cash at beginning of period	22,241	20,666	23,168
Cash at end of period	21,345	22,241	20,666
Supplemental disclosure of cash flow information:	'	'	'
Cash paid for interest	3,973	2,592	2,322
Cash paid for income taxes	1,780	989	523
Purchases of property and equipment in accounts payable	1,513	1,367	3,242
Purchase of property and equipment through capital leases	0	2,225	0
Non-cash purchases of license agreements	250	1,000	8,000
Issuance of common stock in connection with acquisitions	$0	$8,856	$0

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
The Company and Basis of Presentation	'
	The Company and Basis of Presentation
	The Company
	Alphatec Holdings, Inc. (“Alphatec”, “Alphatec Holdings” or the “Company”), through its wholly owned subsidiary, Alphatec Spine, Inc. and its subsidiaries (“Alphatec Spine”) designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its affiliate, Scient’x S.A.S. and its subsidiaries (“Scient’x”), via a direct salesforce in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In South America and Latin America the Company conducts its operations through its Brazilian subsidiary, Cibramed Productos Medicos. In Asia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. and its subsidiaries (“Alphatec Pacific”) via a direct sales force and independent distributors, and through distributors in other parts of Asia and Australia.
	Basis of Presentation
	The consolidated financial statements include the accounts of Alphatec and Alphatec Spine and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the consolidated financial statements.
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. A going concern basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of its liabilities in the normal course of business. Based on the Company’s annual operating plan, management believes that its existing cash of $21 million combined with anticipated cash flow from operations in 2014 and other working capital of $13 million at December 31, 2013 and the Company's available borrowings under credit facilities with MidCap Financial, LLC ("MidCap") and Deerfield (defined in Note 17) will be sufficient to fund its operating cash requirements, including the required payments due under the Orthotec Litigation Settlement (Note 17), through at least December 31, 2014.
	The Company’s credit facility (the “Credit Facility”) with MidCap contains financial covenants consisting of a monthly fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio (see Note 6 and Note 17). Based on the Company’s board-approved current operating plan, the Company believes that it will be in compliance with the financial covenants of the Credit Facility at least through December 31, 2014. However, there is no assurance that the Company will be able to do so. If the Company is not able to achieve its planned revenue or incurs costs in excess of its forecasts, it may be required to substantially reduce discretionary spending and it could be in default of the Credit Facility which would require a waiver from MidCap. There can be no assurance that such a waiver could be obtained, that the Credit Facility could be successfully renegotiated or that the Company can modify its operations to maintain liquidity. If the Company is unable to obtain any required waivers or amendments, MidCap would have the right to exercise remedies specified in the Credit Facility, including accelerating the repayment of debt obligations. The Company may be forced to seek additional financing, which may include additional debt and/or equity financing or funding through other third party agreements. There can be no assurances that additional financing will be available on acceptable terms or available at all. Furthermore, any equity financing may result in dilution to existing stockholders and any debt financing may include restrictive covenants.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the Company’s consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
	Concentrations of Credit Risk and Significant Customers
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and accounts receivable. The Company limits its exposure to credit loss by depositing its cash and cash equivalents with established financial institutions. As of December 31, 2013 a substantial portion of the Company’s available cash funds is in business accounts. Although the Company deposits its cash and cash equivalents with multiple financial institutions, its deposits, at times, may exceed federally insured limits.
	The Company’s customers are primarily hospitals, surgical centers and distributors and no single customer represented greater than 10 percent of consolidated revenues for any of the periods presented. Credit to customers is granted based on an analysis of the customers’ credit worthiness and credit losses have not been significant.
	Revenue Recognition
	The Company derives its revenues primarily from the sale of spinal surgery implants used in the treatment of spine disorders. The Company sells its products primarily through its direct sales force and independent distributors. Revenue is recognized when all four of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured. In addition, the Company accounts for revenue under provisions which sets forth guidelines for the timing of revenue recognition based upon factors such as passage of title, installation, payment and customer acceptance.
	The Company’s revenue from sales of spinal and other surgical implants is recognized upon receipt of written acknowledgement that the product has been used in a surgical procedure or upon shipment to third-party customers who immediately accept title to such implant.
	Deferred revenues consist of products sold to distributors with payment terms greater than the Company’s customary business terms due to lack of credit history or because the distributor is operating in a new market in which the Company has no prior experience. The Company defers the recognition of revenue until payments become due and cash is received from these distributors. As of December 31, 2013 and 2012, the balance in deferred revenue totaled $1.0 million and $1.4 million, respectively.
	Accounts Receivable
	Accounts receivable are presented net of allowance for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for a portion of receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices not specifically reviewed. In determining the provision for invoices not specifically reviewed, the Company analyzes historical collection experience. If the historical data used to calculate the allowance provided for doubtful accounts does not reflect the Company’s future ability to collect outstanding receivables or if the financial condition of customers were to deteriorate, resulting in impairment of their ability to make payments, an increase in the provision for doubtful accounts may be required.
	Inventories
	Inventories are stated at the lower of cost or market, with cost primarily determined under the first-in, first-out method. The Company reviews the components of inventory on a periodic basis for excess, obsolete and impaired inventory, and records a reserve for the identified items. The Company calculates an inventory reserve for estimated excess and obsolete inventory based upon historical turnover and assumptions about future demand for its products and market conditions. The Company’s biologics inventories have an expiration based on shelf life and are subject to demand fluctuations based on the availability and demand for alternative implant products. The Company’s estimates and assumptions for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the reserve for excess and obsolete inventory result in a corresponding increase to cost of revenues and establish a new cost basis for the part. Approximately $18.4 million and $22.0 million of inventory was held at consigned locations as of December 31, 2013 and 2012, respectively.
	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally ranging from three to seven years. Leasehold improvements and assets acquired under capital leases are amortized over the shorter of their useful lives or the terms of the related leases.
	Goodwill and Other Intangible Assets
	The Company accounts for goodwill and other intangible assets in accordance with provisions which require that goodwill and other identifiable intangible assets with indefinite useful lives be tested for impairment at least annually. The Company tests goodwill and intangible assets for impairment in December of each year, or more frequently if events and circumstances warrant. These assets are impaired if the Company determines that their carrying values may not be recoverable based on an assessment of certain events or changes in circumstances. If the assets are considered to be impaired, the Company recognizes the amount by which the carrying value of the assets exceeds the fair value of the assets as an impairment loss. During the year ended December 31, 2013, the Company decided that it would not continue to market an adult stem cell product sold under the Company's private label name of Puregen. The Company also decided that it would no longer actively market two additional products. The Company expensed $1.3 million as impairment charges in cost of goods sold in the year ended December 31, 2013 for the write-off of intangible assets related to these products.
	The Company estimated the fair value in step one of the goodwill impairment test based on a combination of the income approach which included discounted cash flows as well as a market approach that utilized the Company’s market information. The income approach fair value measurements are categorized within Level 3 of the fair value hierarchy. The Company’s discounted cash flows required management judgment with respect to forecasted sales, launch of new products, gross margin, selling, general and administrative expenses, capital expenditures and the selection and use of an appropriate discount rate and terminal rate. For purposes of calculating the discounted cash flows, the Company used estimated revenue growth rates averaging between 4% and 12% for the discrete forecast period. Cash flows beyond the discrete forecasts were estimated using a terminal value calculation, which incorporated historical and forecasted financial trends and considered long-term earnings growth rates for publicly traded peer companies. Future cash flows were then discounted to present value at a discount rate of 12%, and terminal value growth rate of 4%. Publicly available information regarding comparable market capitalization was also considered in assessing the reasonableness of the Company’s fair value. The Company’s assessment resulted in a fair value that was greater than the Company’s carrying value at December 31, 2013. In accordance with the authoritative literature, the second step of the impairment test was not required to be performed and thus no impairment of goodwill was recorded as of December 31, 2013.
	Significant management judgment is required in the forecast of future operating results that are used in the Company’s impairment analysis. The estimates the Company used are consistent with the plans and estimates that it uses to manage its business. Significant assumptions utilized in the Company’s income approach model included the growth rate of sales for recently introduced products and the introduction of anticipated new products similar to its historical growth rates. Another important assumption involved in forecasted sales is the projected mix of higher margin U.S. based sales and lower margin non-U.S. based sales. Additionally, the Company has projected an improvement in its gross margin, similar to its historical improvement in gross margins, as a result of its forecasted mix in U.S. sales versus non-U.S. based sales and lower manufacturing cost per unit based on the increase in forecasted volume to absorb applied overhead over the next ten years. Although the Company believes its underlying assumptions supporting this assessment are reasonable, if the Company’s forecasted sales, mix of product sales, growth rates of recently introduced new products, timing of and growth rates of new product introductions, gross margin, selling, general and administrative expenses, or the discount rate vary from its forecasts, the Company could be exposed to material impairment charges in the future. Additionally, if the Company’s stock price decreases significantly from the closing price on December 31, 2013, the Company may be required to perform an interim analysis in 2014 that could result in an impairment charge.
	The accounting provisions also require that intangible assets with definite useful lives be amortized over their respective estimated useful lives and reviewed for indicators of impairment. The Company is amortizing its intangible assets, other than goodwill, on a straight-line basis over a one to fifteen-year period.
	Impairment of Long-Lived Assets
	The Company assesses potential impairment to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the carrying amount of the long-lived assets is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results.
	Due to the Scient'x restructuring plan, the Company assessed potential impairment on certain intangible assets related to the Scient'x acquisition. Based on this assessment the projected undiscounted cash flows exceeded the carrying amount of the intangible assets and no impairment loss was recognized in the year ended December 31, 2013.
	Foreign Currency
	The Company’s results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. The Company’s primary functional currency is the U.S. dollar, while the functional currency of the Company’s Japanese subsidiary is the Japanese Yen, the Hong Kong subsidiary is the Hong Kong dollar and the functional currency of the Company’s European operations is the Euro. Assets and liabilities denominated in foreign currencies are translated at the rate of exchange on the balance sheet date. Revenues and expenses are translated using the average exchange rate for the period. Net gains and losses resulting from the translation of foreign financial statements are recorded as accumulated other comprehensive income (loss) in stockholders’ equity. Net foreign currency gains or (losses) resulting from transactions in currencies other than the functional currencies are included in other income (expense), net in the accompanying consolidated statements of operations. For the years ended December 31, 2013, 2012 and 2011, the Company recorded net foreign currency gains (losses) of approximately $(1.7) million, $(0.9) million and $0.5 million, respectively.
	Fair Value of Financial Instruments
	The carrying value of accounts receivable, foreign cash accounts, prepaid expenses, other current assets, accounts payable, accrued expenses, and current portion of debt are considered to be representative of their respective fair values because of the short- term nature of those instruments. Based on the borrowing rates currently available to the Company for loans with similar terms, management believes the fair value of notes payable, capital leases and other long-term debt approximates their carrying values.
	The Company measures its fair value of financial instruments in accordance with the established framework for fair value using “levels” which are defined as follows: Level 1 fair value is determined from observable, quoted prices in active markets for identical assets or liabilities. Level 2 fair value is determined from quoted prices for similar items in active markets or quoted prices for identical or similar items in markets that are not active. Level 3 fair value is determined using the entity’s own assumptions about the inputs that market participants would use in pricing an asset or liability.
	The Company reassesses the fair value of contingent consideration of $3.8 million to be settled in cash related to acquisitions on a quarterly basis using the present value of future royalty payments due. This is a Level 3 measurement. Significant assumptions used in the measurement include estimates of the royalty payments due.
	Research and Development
	Research and development expense consists of costs associated with the design, development, testing, and enhancement of the Company’s products. Research and development costs also include salaries and related employee benefits, research-related overhead expenses, fees paid to external service providers, and costs associated with the Company’s Scientific Advisory Board and Executive Surgeon Panels. Research and development costs are expensed as incurred.
	In-Process Research and Development
	In-process research and development (“IPR&D”) consists of acquired research and development assets that are not part of an acquisition of a business and were not technologically feasible on the date the Company acquired them and had no alternative future use at that date or IPR&D assets acquired in a business acquisition that are determined to have no alternative future use. The Company expects all acquired IPR&D will reach technological feasibility, but there can be no assurance that commercial viability of these products will ever be achieved. The nature of the efforts to develop the acquired technologies into commercially viable products consists principally of planning, designing, developing and testing products in order to obtain regulatory approvals. If commercial viability were not achieved, the Company would likely look to other alternatives to provide these products. Until the technological feasibility of the acquired research and development assets are established, the Company expenses these costs.
	Leases
	The Company leases its facilities and certain equipment and vehicles under operating leases, and certain equipment under capital leases. For facility leases that contain rent escalation or rent concession provisions, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease. The Company records the difference between the rent paid and the straight-line rent as a deferred rent liability in the accompanying consolidated balance sheets.
	Product Shipment Cost
	Product shipment costs are included in sales and marketing expense in the accompanying consolidated statements of operations. Product shipment costs totaled $3.1 million, $2.9 million and $3.6 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Stock-Based Compensation
	The Company accounts for stock-based compensation under provisions which require that share-based payment transactions with employees be recognized in the financial statements based on their fair value and recognized as compensation expense over the vesting period. The amount of expense recognized during the period is affected by subjective assumptions, including: estimates of the Company’s future volatility, the expected term for its stock options, the number of options expected to ultimately vest, and the timing of vesting for the Company’s share-based awards.
	The Company uses a Black-Scholes-Merton option-pricing model to estimate the fair value of its stock option awards. The calculation of the fair value of the awards using the Black-Scholes-Merton option-pricing model is affected by the Company’s stock price on the date of grant as well as assumptions regarding the following:
	•	Estimated volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate each year during the expected life of the award. The Company’s estimated volatility through December 31, 2013 was based on a weighted-average volatility of its actual historical volatility over a period equal to the expected life of the awards.
	•	The expected term represents the period of time that awards granted are expected to be outstanding. Through December 31, 2013, the Company calculated the expected term using a weighted-average term based on historical exercise patterns and the term from option date to full exercise for the options granted within the specified date range.
	•	The risk-free interest rate is based on the yield curve of a zero-coupon U.S. Treasury bond on the date the stock option award is granted with a maturity equal to the expected term of the stock option award.
	•	The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future.
	The Company used historical data to estimate the number of future stock option forfeitures. Share-based compensation recorded in the Company’s consolidated statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures. The Company’s estimated forfeiture rates may differ from its actual forfeitures which would affect the amount of expense recognized during the period.
	The Company values equity awards with a market condition using a Monte Carlo simulation model.
	The Company accounts for stock option grants to non-employees in accordance with provisions which require that the fair value of these instruments be recognized as an expense over the period in which the related services are rendered.
	Share-based compensation expense of awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met. Determining the likelihood and timing of achieving performance conditions is a subjective judgment made by management which may affect the amount and timing of expense related to these share-based awards. Share-based compensation is adjusted to reflect the value of options which ultimately vest as such amounts become known in future periods.
	Valuation of Stock Option Awards
	The assumptions used to compute the share-based compensation costs for the stock options granted during the years ended December 31, 2013, 2012 and 2011 are as follows:
		Year Ended December 31,
		2013			2012			2011
	Risk-free interest rate	1.1-1.8%			0.9-1.2%			1.2-2.5%
	Expected dividend yield	—			—			—
	Weighted average expected life (years)	5.3-5.5			5.3-5.8			5.8-5.9
	Volatility	75-76%			75-78%			56-57%
	Compensation Costs
	The compensation cost that has been included in the Company’s consolidated statement of operations for all stock-based compensation arrangements is detailed as follows (in thousands, except per share amounts):
		Year Ended December 31,
		2013				2012			2011
	Cost of revenues	$	228			$	137		$	180
	Research and development	719				261			289
Sales and marketing	459				1,695			693
General and administrative	2,672				1,447			1,263
Total	$	4,078			$	3,540		$	2,425
The amounts above include stock-based compensation expense of $1.5 million, $1.3 million and $0 million during the years ended December 31, 2013, 2012 and 2011, respectively, related to the vesting of stock options and awards granted to non-employees under consulting agreements.
Income Taxes
The Company accounts for income taxes in accordance with provisions which set forth an asset and liability approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In making such determination, a review of all available positive and negative evidence must be considered, including scheduled reversal of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.
The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision.
Net Loss per Share
Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive. (In thousands, except per share data):
	Year Ended December 31,
	2013				2012			2011
Numerator:
Net loss	$	(82,227	)		$	(15,459	)	$	(22,181	)
Denominator:
Weighted average common shares outstanding	97,111				90,870			89,165
Weighted average unvested common shares subject to repurchase	(876		)		(652		)	(368		)
Weighted average common shares outstanding—basic	96,235				90,218			88,797
Effect of dilutive securities:
Options, warrants and restricted share awards	—				—			—
Weighted average common shares outstanding—diluted	96,235				90,218			88,797
Net loss per common share:
Basic and diluted net loss per share	$	(0.85	)		$	(0.17	)	$	(0.25	)
As of December 31, 2013, 2012 and 2011, none of the outstanding redeemable preferred stock is convertible to common stock.
The weighted-average anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
	Year Ended December 31,
	2013			2012			2011
Options to purchase common stock	4,597			4,621			4,323
Warrants to purchase common stock	594			594			94
Unvested restricted stock awards	807			877			368
	5,998			6,092			4,785
Recent Accounting Pronouncements
In February 2013, the FASB issued guidance that requires a company to disaggregate the total change of each component of other comprehensive income either on the face of the income statement or as a separate disclosure in the notes. The new guidance became effective for our interim period ended March 31, 2013. The Company adopted this guidance and the adoption did not have any impact on its financial position, results of operations or cash flows.
In March 2013, the FASB issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments are effective for the Company beginning January 1, 2014. The Company does not anticipate any impact on its financial statements upon adoption.
In July 2013, the FASB issued guidance that requires an unrecognized tax benefit, or a portion of an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless an exception applies. The Company early adopted this guidance for the period ending December 31, 2013, which is reflected in the Company's consolidated financial statements as of and for the period ended December 31, 2013. There was no material impact on the Company's financial statements upon adoption.

Acquisitions_and_Investment

Acquisitions and Investment	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions and Investment	'
	Acquisitions and Investment
	Acquisition of Phygen, LLC
	On November 6, 2012, the Company closed the acquisition pursuant to the Asset Purchase Agreement (the “Asset Purchase Agreement”) with Phygen, LLC (“Phygen”), pursuant to which the Company agreed to purchase Phygen’s right, title and interest in and certain assets used by Phygen in connection with the design, development, marketing and distribution of certain of Phygen’s spinal implant products, together with the intellectual property rights, contractual rights, inventories and certain liabilities related thereto. At the closing of the transaction the Company issued to Phygen 4,069,087 unregistered shares of the Company’s common stock and paid to Phygen $2 million in cash. The Company placed 1,170,960 unregistered shares of the common stock into an escrow account, which served as security against any potential indemnification obligations of Phygen under the Asset Purchase Agreement for a period of 12 months following the closing. In November 2013, the Company made a claim of 328,356 shares of the Company's common stock against the escrow shares, which were returned to the Company in December 2013. In connection with this release of shares the Company recorded income of $0.6 million as a reduction of general and administrative expenses in the year ended December 31, 2013. The remaining shares of the Company's common stock held in escrow were released to the owners of Phygen. In addition, pursuant to the Asset Purchase Agreement, the Company paid to Phygen $4 million in cash in April 2013. In connection with the Phygen acquisition, the Company incurred transaction related expenses of $1.1 million in the year ended December 31, 2012. The results of Phygen’s operations are included in the consolidated financial statements from November 7, 2012.
	Based on the closing price of Alphatec’s common stock of $1.69 on November 6, 2012, cash consideration and contingent liabilities, the total purchase price was as follows (in thousands):
	Fair value of Alphatec common stock issued upon closing	$	8,856
	Cash consideration paid and payable	5,900
	Contingent consideration	3,724
	Total purchase price	$	18,480
	Under the acquisition method of accounting, the total purchase price was allocated to Phygen’s net tangible and intangible assets was based on their estimated fair values at the date of the completion of the acquisition.
	The following table summarizes the allocation of the purchase price for Phygen and the estimated useful lives for the acquired intangible assets (in thousands):
		Useful lives		Estimated
		(in years)		Fair Value
	Net tangible assets assumed			$	1,086
	Acquired intangibles:
	Developed technology	3		176
	Trademarks	3		59
	Covenant not-to-compete	3		389
	Customer-related intangible	12		5,843
	Distribution network	12		2,413
	Goodwill			8,514
	Total purchase price allocation			$	18,480
	The Company allocated $1.1 million to Phygen’s net tangible assets assumed, and $8.9 million to identifiable intangible assets acquired and $3.7 million to contingent consideration. A value of $8.5 million, representing the difference between the total purchase price and the aggregate fair values assigned to the net tangible and intangible assets acquired, less liabilities and contingent consideration assumed, was assigned to goodwill. The Company acquired Phygen to expand its product offerings to Phygen’s existing surgeon base. This and other factors contributed to a purchase price for Phygen that resulted in the recognition of goodwill. The amount recorded as acquired intangibles and goodwill is expected to be deductible for tax purposes.
	The Company increased the value of inventory it acquired from Phygen to its estimated fair value (“step up”), which represented an amount equivalent to estimated selling prices less distribution related costs and a normative selling profit. Consistent with stock rotation, the inventory step up reversed ratably over 6 months and is included in the Company’s post-combination financial statements.
	For the technology-related assets, the Company determined the values for each of these categories by estimating the present values of the net cash flows expected to be generated by each category of technology.
	The Company calculated the value of the trademark by estimating the present value of future royalty costs that would be avoided by a market participant due to ownership of the trademarks acquired.
	The Company calculated the value of the covenant not-to-compete by estimating the difference between the present value of future cash flows with and without the covenant not-to-compete in place.
	The customer-related intangible includes hospitals and distributors that take title to Phygen’s products. The Company determined the value of such customer-related intangible by estimating the present value of expected future net cash flows derived from such customers.
	The distribution network includes U.S.-based distributors that sell Phygen’s products to customers on a consignment basis. The Company determined the value of the intangibles related to the distribution network by estimating the difference between the present values of expected future net cash flows generated with and without the distribution network in place.
	The Company calculated the value of the contingent consideration by estimating the present value of future minimum royalty payments due under licensing agreements entered into in connection with the Phygen acquisition. The Company will revalue the contingent consideration each reporting period with an offset to any increase or decrease in the statement of operations.
	Pro forma supplemental financial information is not provided as the impact of the Phygen acquisition was not material to operating results in the year ended December 31, 2013 or 2012.
	Acquisition of Cibramed
	In January 2011, the Company acquired Cibramed Productos Medicos (“Cibramed”), a Brazilian medical device company. The Company purchased Cibramed to acquire its ANVISA regulatory registration certificates and its general licenses to conduct business in Brazil. The Company recorded an intangible asset of $0.6 million for the ANVISA regulatory registration certificates and licenses it purchased. The Company is amortizing this asset on a straight-line basis over its estimate life of 15 years. No product distribution rights were acquired. The purchase price of $0.6 million was paid in installments consisting of (i) 60% upon execution of the acquisition agreement; (ii) 20% due 90 days from the execution of the acquisition agreement and; (iii) 20% due 180 days from the execution of the acquisition agreement. The Company paid the full purchase price of $0.6 million in 2011.

Balance_Sheet_Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2013
Balance Sheet Related Disclosures [Abstract]	'
Balance Sheet Details	'
	Balance Sheet Details
	Accounts Receivable
	Accounts receivable consist of the following (in thousands):
		December 31,
		2013				2012
	Accounts receivable	$	42,443			$	42,086
	Allowance for doubtful accounts	(1,048		)		(1,074		)
	Accounts receivables, net	$	41,395			$	41,012
	Inventories
	Inventories consist of the following (in thousands):
		31-Dec-13										31-Dec-12
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	4,375			$	—			$	4,375	$	5,863	$	—		$	5,863
	Work-in-process	531				—				531		1,350		—			1,350
	Finished goods	60,979				(23,946		)		37,033		59,864		(17,222		)	42,642
	Inventories	$	65,885			$	(23,946	)		$	41,939	$	67,077	$	(17,222	)	$	49,855
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		Useful lives		December 31,
		(in years)		2013				2012
	Surgical instruments	4		$	62,636			$	56,712
	Machinery and equipment	7		14,692				13,996
	Computer equipment	3		3,357				3,269
	Office furniture and equipment	5		3,703				3,528
	Leasehold improvements	various		4,161				4,092
	Building	39		52				64
	Land	n/a		10				13
	Construction in progress	n/a		1,228				1,045
				89,839				82,719
	Less accumulated depreciation and amortization			(61,809		)		(52,316		)
	Property and equipment, net			$	28,030			$	30,403
	Total depreciation expense was $14.6 million, $14.2 million and $14.8 million for the years ended December 31, 2013, 2012 and 2011, respectively. At December 31, 2013 and 2012, assets recorded under capital leases of $1.8 million are included in the machinery and equipment balance and $0.6 million are included in the construction in progress balance. Amortization of assets under capital leases is included in depreciation expense.
	Intangible Assets
	Intangibles assets consist of the following (in thousands):
		Useful lives		December 31,
		(in years)		2013				2012
	Developed product technology	8-Mar		$	23,633			$	23,253
	Distribution rights	3		2,343				4,281
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		17,686				17,423
	Core technology	10		5,137				4,940
	Trademarks and trade names	9-Mar		3,920				3,796
	Customer-related	15-Dec		22,161				19,221
	Distribution network	12-Oct		4,027				3,906
	Physician education programs	10		3,160				3,039
	Supply agreement	10		225				225
				83,296				81,088
	Less accumulated amortization			(44,232		)		(34,232		)
	Intangible assets, net			$	39,064			$	46,856
	Total amortization expense was $11.6 million, $9.6 million and $5.1 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	During the year ended December 31, 2013, the Company decided that it would not continue to market an adult stem cell product sold under the Company's private label name of Puregen. The Company also decided that it would no longer actively market two additional products. The Company expensed $1.3 million as impairment charges in cost of goods sold in the year ended December 31, 2013 for the write-off of intangible assets related to these products.
	The future expected amortization expense related to intangible assets as of December 31, 2013 is as follows (in thousands):
	Year Ending December 31,
	2014	$	6,751
	2015	6,102
	2016	5,608
	2017	4,986
	2018	3,279
	Thereafter	12,338
	Total	$	39,064
	Accrued Expenses
Accrued expenses consist of the following (in thousands):
	December 31,
	2013				2012
Legal	$	2,139			$	939
Accounting	928				847
Phygen purchase price	—				3,936
Severance	297				749
Restructuring	9,170				—
Sales milestones	1,828				2,423
Accrued taxes	1,120				1,605
Deferred rent	1,163				1,483
Royalties	2,347				1,911
Commissions	6,180				5,371
Payroll and related	9,369				7,027
Litigation settlements	22,600				4,102
Other	5,855				8,097
Total accrued expenses	$	62,996			$	38,490
Goodwill
The changes in the carrying amount of goodwill from December 31, 2012 through December 31, 2013 were as follows (in thousands):
	December 31,
	2013				2012
Balance at December 31, 2012 and 2011	$	180,838			$	168,609
Change in Phygen goodwill	(1,610		)		10,124
Effect of foreign exchange rate on goodwill	3,776				2,105
Balance at December 31,	$	183,004			$	180,838

License_and_Consulting_Agreeme

License and Consulting Agreements	12 Months Ended
	Dec. 31, 2013
License and Consulting Agreements [Abstract]	'
License and Consulting Agreements	'
	License and Consulting Agreements
	License Agreements
	In June 2012, the Company entered into a private label supply agreement with a third party supplier whereby the Company acquired exclusive U.S. distribution rights to market a patented synthetic biologic product under its own brand name (the “Biologic Supply Agreement”). The Company made an up-front payment of $1.0 million in connection upon the execution of the Biologic Supply Agreement. The up-front payment was capitalized as an intangible asset and will be amortized straight-line over the 4-year term of the Biologic Supply Agreement.
	In October 2012, the Company entered into a supply agreement with a third party supplier whereby the Company acquired exclusive worldwide distribution rights to sell an anchored, fully retractable cervical inter-body spacer (the “Cervical Spacer Supply Agreement”). The Company was required to make up-front payments totaling $1.0 million upon the execution of the Cervical Spacer Supply Agreement. The $1.0 million up-front payments were capitalized as an intangible asset and will be amortized over the 7-year term of the Cervical Spacer Supply Agreement. Additionally, the Company is required to meet certain minimum purchase requirements of up to $5.9 million per year to maintain its exclusive distribution rights.
	OsseoFix Spinal Fracture Reduction System License Agreement
	On April 16, 2009, the Company and Stout Medical Group LP (“Stout”) amended the license agreement that the parties had entered into in September 2007 (the “License Amendment”) that provides the Company with a worldwide license to develop and commercialize Stout’s proprietary intellectual property related to a treatment for vertebral compression fractures. The effective date of the License Amendment is March 31, 2009. Under the License Amendment, the timing of the minimum royalty payments has been adjusted and Stout’s ability to terminate the License Amendment was revised. Under the original license agreement, the Company’s minimum royalty obligation began in the year ending December 31, 2009 and there are milestones due upon attainment of sales volumes. Pursuant to the License Amendment, the minimum royalty obligation is suspended until a licensed product obtains regulatory approval from the United States Food and Drug Administration (the “FDA”). In addition, under the terms of the License Amendment, Stout has the ability to terminate the License Amendment if the Company is not using commercially reasonable efforts to obtain regulatory approval to market and sell a licensed product; provided that the Company has the right to delay such termination in exchange for making certain payments to Stout. If, during the time period when such payments are made, the Company were to make a regulatory filing for the marketing and sale of a licensed product, such termination will be null and void. Pursuant to the License Amendment, Stout is entitled to retain all up-front payments that had been previously paid to it. The other material terms of the license agreement were not changed in the License Amendment.
	OsseoScrew License Agreement
	In December 2007, the Company entered into an exclusive license agreement (the “OsseoScrew License Agreement”), with Progressive Spinal Technologies LLC (“PST”), which provides the Company with an exclusive worldwide license to develop and commercialize PST’s proprietary intellectual property related to an expanding pedicle screw with increased pull-out strength. The financial terms of the OsseoScrew License Agreement include: (i) a cash payment payable following the execution of the agreement; (ii) development and sales milestone payments in cash and the Company’s common stock that began to be achieved and paid in 2008; and (iii) a royalty payment based on net sales of licensed products. The agreement included milestone payments of $3.6 million consisting of cash and the Company’s common stock upon the completion of the biomechanical testing, which were attained in 2009. Furthermore, the agreement includes milestone payments of $2.5 million consisting of cash and the Company’s common stock upon market launch.
	In November 2010, the Company and PST entered into a fifth amendment to the OsseoScrew License Agreement. The fifth amendment includes (i) a milestone payment of a $1.5 million and the issuance of $1.0 million in shares of the Company’s common stock upon market launch in Europe; and (ii) royalty payments based on net sales of licensed products with minimum annual royalties beginning at the end of 2011. During the fourth quarter of 2010, the Company recorded an intangible asset of $2.5 million for a milestone payment required upon market launch in Europe which consisted of the cash payment of $1.5 million and $1.0 million in shares of the Company’s common stock. The Company is amortizing this asset over seven years, the estimated life of the product. The total number of shares of common stock which were issued on December 15, 2010, was 452,488.
	On December 12, 2013, the Company and PST entered into a sixth amendment to the OsseoScrew License Agreement. The sixth amendment provides (i) the royalty rate paid by the Company for net sales of licensed products is increased; (ii) the territory is amended so that the United States is removed from the territory in which the Company can sell and market licensed products, and such rights are non-exclusive in Russia and the People’s Republic of China; (iii)  all milestone payments based on the achievement of certain sales milestones are deleted; and (iv) a $0.3 million milestone payment to be paid upon the achievement of regulatory approval of a licensed product in the People’s Republic of China was added. In connection with this amendment the company reversed the $0.6 million accrual it had recorded for the sales milestone payment into cost of goods sold for the year ended December 31, 2013.
	License Agreement with Helix Point, LLC
	In February 2009, the Company entered into a license agreement (the “Helifuse/Helifix License Agreement”) with Helix Point, LLC (“Helix Point”) that provides the Company with a worldwide exclusive license (excluding the People’s Republic of China) to develop and commercialize Helix Point’s proprietary intellectual property related to a device for the treatment of spinal stenosis. The financial terms of the Helifuse/Helifix License Agreement include: (i) a cash payment of $0.2 million payable following the execution of the Helifuse/Helifix License Agreement; (ii) the issuance of $0.4 million of shares of the Company’s common stock following the execution of the Helifuse/Helifix License Agreement; (iii) development and sales milestone payments in cash and the Company’s common stock; and (iv) a royalty payment based on net sales of licensed products, with minimum annual royalties beginning in the year after the first commercial sale of a licensed product. During the third quarter of 2010, the Company recorded an intangible asset of $0.2 million for the assets received as this product is cleared for sale in Europe and technological feasibility is considered to have been achieved. The Company is amortizing this asset over seven years, the estimated life of the product.
	License Agreement with International Spinal Innovations, LLC
	In June 2009, the Company entered into a cross license agreement (the “ISI License Agreement”) with International Spinal Innovations, LLC (“ISI”) that provides the Company with a worldwide license to develop and commercialize ISI’s proprietary intellectual property related to a stand-alone anterior lumbar interbody fusion device. The financial terms of the ISI License Agreement include: (i) the issuance of 260,000 shares of the Company’s common stock following the execution of the ISI License Agreement; (ii) sales milestone payments in cash that could begin to be achieved and paid in 2014; and (iii) a royalty payment based on net sales of licensed products. In 2012, the Company entered into an amended agreement that established a minimum royalty payment amount that began in 2012.
	Distribution Agreement with Parcell Spine, LLC
	In January 2010, the Company entered into an exclusive distribution agreement (the “Parcell Agreement”) with Parcell Spine, LLC (“Parcell Spine”), which provides the Company with the exclusive right to distribute Parcell Spine’s proprietary adult stem cells for the treatment of spinal disorders under either Parcell’s trademarks or Alphatec Spine’s private label. The financial terms of the Parcell Agreement include: (i) a cash payment of $0.5 million payable following the execution of the Parcell Agreement; (ii) a milestone payment consisting of $1.0 million in cash and the issuance of $1.0 million of shares of the Company’s common stock following the successful completion of a pre-clinical study; and (iii) sales milestone payments in cash and the Company’s common stock. During the first quarter of 2010, the Company recorded an IPR&D charge of $0.5 million for the initial cash payment. During the third quarter of 2010, the pre-clinical study milestone was achieved and the Company recorded an IPR&D charge totaling $2.0 million, which consisted of a cash payment of $1.0 million and the issuance of $1.0 million worth of the Company’s common stock. The amounts were expensed as the technological feasibility associated with the IPR&D had not been established since the final prototype of the device had not been completed, additional items subject to risk of completion were necessary to comply with regulatory requirements and no alternative future use exists. The total number of shares of common stock, which were issued in accordance with the agreement for the achievement of a development milestone, was 465,116. In addition, during the third quarter of 2010, the Company recorded an intangible asset of $1.5 million for a milestone payment required upon market launch when the product became commercially ready for sale which consisted of a cash payment of $0.5 million and $1.0 million worth of the Company’s common stock. The Company is amortizing this asset over seven years, the estimated life of the product. The total number of shares of common stock, which were issued in accordance with the agreement for the achievement of a development milestone in September 2010, was 476,190.
	During the year ended December 31, 2013, the Company decided that it would not continue to sell its Puregen product, which is currently the only product commercialized by the Company under the Parcell Agreement. During the year ended December 31, 2013, the Company expensed $0.9 million as impairment charges in cost of goods for the write-off of intangible assets related to the Parcell Agreement and expensed $2.6 million related to the write-off of inventory and certain prepaid assets in cost of goods sold.
	License Agreement with R Tree Innovations LLC
	In September 2010, the Company entered into a License Agreement (the “R Tree License Agreement”) with R Tree Innovations LLC (“R Tree”) that provides the Company with a worldwide license to develop and commercialize R Tree’s proprietary intellectual property related to its Epicage interbody fusion device and related instrumentation. The financial terms of the R Tree License Agreement include: (i) a cash payment of $0.8 million and the issuance of $0.5 million of the Company’s common stock following the execution of the R Tree License Agreement; (ii) development and sales milestone payments in cash that could begin to be achieved and paid in 2013; and (iii) a royalty payment based on net sales of licensed products. During the third quarter of 2010, the Company recorded an intangible asset of $1.3 million following the execution of the R Tree License Agreement. In November 2012, the Company and R Tree entered into an amendment to the R Tree License Agreement (the “R Tree Amendment”). In connection with the R Tree Amendment the Company made a cash payment of $0.3 million and issued $0.2 million worth of its common stock to R Tree. The total consideration of $0.5 million was recorded as an intangible asset. The Company is amortizing the intangible asset over seven years, the estimated life of the product. The total number of shares of common stock, which were issued in accordance with the R Tree License Agreement and the R Tree Amendment was 367,044. In October 2013, another milestone was reached and the Company made a $0.3 million cash payment and will issue $0.2 million worth of its common stock to R Tree. The total consideration of $0.5 million was recorded as an intangible asset.

Debt

Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	MidCap Loan and Security Agreement
	On August 30, 2013, the Company entered into an Amended and Restated Credit, Security and Guaranty Agreement (the "Amended Credit Facility") with MidCap. The Amended Credit Facility amended and restated the prior credit facility that the Company had MidCap (the "Credit Facility").
	Pursuant to the Amended Credit Facility, the Company increased the borrowing limit from $50 million to $73 million. The Company also extended the maturity to August 2016. The Amended Credit Facility consists of a $28 million term loan drawn at closing with a $5 million delayed draw within 12 months, for a total term loan maximum borrowing of $33 million and a revolving line of credit with a maximum borrowing base of $40 million. The Company used the term loan proceeds of $28 million to repay a portion of the outstanding balance on the prior revolving line of credit.
	The term loan interest rate is priced at the London Interbank Offered Rate ("LIBOR") plus 8.0%, subject to a 9.5% floor, and the revolving line of credit interest rate bears interest at LIBOR plus 6.0%, reset monthly. At December 31, 2013, the revolving line of credit carried an interest rate of 6.2% and the term loan carried an interest rate of 9.5%. The borrowing base is determined, from time to time, based on the value of domestic eligible accounts receivable and domestic eligible inventory. As collateral for the Amended Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries.
	In addition to monthly payments of interest, monthly repayments of $0.3 million of the principal for the term loan are due beginning in October 2013 through maturity, with the remaining principal due upon maturity.
	In connection with the execution of the Amended Credit Facility, the Company incurred approximately $0.4 million in costs were capitalized as debt issuance costs. Approximately $0.4 million of the net remaining unamortized debt issuance costs related to the prior Credit Facility remained within the unaudited consolidated balance sheets, which will be amortized over the term of the Amended Credit Facility.
	On June 7, 2012, the Company entered into the prior Credit Facility with MidCap, which permitted the Company to borrow up to $40 million under a revolving line of credit and included an option to increase the borrowing base to $50 million with the prior consent of MidCap. As collateral for the Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries.
	Upon execution of the prior Credit Facility, the Company drew $34.3 million on the Credit Facility to pay off its existing term loan with Silicon Valley Bank (“SVB”) totaling $8.1 million and its existing line of credit with SVB totaling $17.6 million (collectively the “SVB Credit Facility”). The Company paid early termination and other fees to SVB associated with the SVB Credit Facility of $2.3 million and wrote-off $0.6 million of unamortized debt issuance and debt discount costs related to the SVB Credit Facility. The total loss on extinguishment of debt costs of $2.9 million is included in interest expense in the nine months ended September 30, 2012. The Company paid an up-front commitment fee to MidCap of $0.2 million and debt issuance costs of $0.2 million, which were capitalized as deferred debt issuance costs.
	The Amended Credit Facility includes traditional lending and reporting covenants including a fixed charge coverage ratio and a senior leverage ratio to be maintained by the Company. The Amended Credit Facility also includes several potential events of default, such as payment default and insolvency conditions, which could cause interest to be charged at a rate which is up to five percentage points above the rate effective immediately before the event of default or result in MidCap’s right to declare all outstanding obligations immediately due and payable. In January 2013, the Company entered into a limited waiver and limited consent agreement with MidCap (the “Waiver”). Under the Waiver, MidCap gave the Company its consent to waive certain provisions of the prior Credit Facility in connection with the acquisition of Phygen and related to the maintenance of cash balances in the U.S. In February 2013, the Company and MidCap entered into a first amendment to the Credit Facility (the First Amendment”). The First Amendment allowed the Company to exclude payments related to the Phygen acquisition and the settlement agreement with Cross Medical Products, LLC (“Cross”) from calculation of the fixed charge coverage ratio and the senior leverage ratio. In conjunction with the First Amendment, the Company paid MidCap a fee of $0.1 million. In July 2013, the Company entered into a second limited waiver and limited consent agreement with MidCap (the “Second Waiver”). Under the Second Waiver, MidCap gave the Company its consent to waive certain provisions of the prior Credit Facility related to the maintenance of cash balances in the U.S. for past periods through September 30, 2013. On August 30, 2013, the Company entered into the Amended Credit Agreement with MidCap. The Company was in compliance with all of the covenants of the Amended Credit Facility as of December 31, 2013.
	During the year ended December 31, 2013, the Company repaid $168.9 million, including a $28.0 million repayment using the proceeds from the new term loan, and drew an additional $154.6 million on its working capital line of credit. The balance of the line of credit and the term loan as of December 31, 2013 was $24.8 million and $27.3 million, respectively. Amortization of the debt discount and debt issuance costs, accretion of the finance charge and non-cash extinguishment of debt costs, which were recorded as non-cash interest expense, totaled $0.2 million, $0.9 million and $0.4 million for the years ended December 31, 2013, 2012 and 2011, respectively. Interest expense for the term loans and the Company’s working capital line of credit, excluding debt discount and debt issuance cost amortization, accretion of the additional finance charge and extinguishment of debt costs, totaled $3.6 million, $2.6 million and $2.2 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	SVB Loan and Security Agreement
	On October 29, 2010, the Company entered into an amended and restated loan and security agreement with SVB (the “SVB Credit Facility”), which was amended in December 2011. The amended SVB Credit Facility consisted of a working capital line of credit, which permitted the Company to borrow up to $22 million and a $10 million term loan. The actual amount available was based on eligible accounts receivable and eligible inventory. The term loan carried a fixed interest rate equal to the greater of 8.5% or the SVB prime rate plus 4.5% with principal plus interest repayments due in 16 equal quarterly installments. The term loan matured October 2015 and the Company was subject to a prepayment penalty if the term loan is repaid prior to maturity. In June 2012, the SVB Credit Facility was terminated and replaced by the MidCap Credit Facility.
	Other Debt Agreements
	The Company has various capital lease arrangements. The leases bear interest at rates ranging from 6.6% to 9.6%, are generally due in monthly principal and interest installments, are collateralized by the related equipment, and have various maturity dates through June 2017.
	Long-term debt consists of the following (in thousands):
		December 31,
		2013			2012
	Credit Facility with MidCap	$	52,081		$	38,634
	Capital leases (See Note 7)	1,336			1,770
	Note payable related to software license purchases	58			59
	Financing agreements for premiums on insurance policies	1,427			1,204
	Total debt	54,902			41,667
	Less: current portion	(4,924		)	(1,700		)
	Total long-term debt	$	49,978		$	39,967
	Principal payments on debt are as follows as of December 31, 2013 (in thousands):
	Year Ending December 31,
	2014	$	4,485
	2015	3,000
	2016	46,081
	2017	—
	2018	—
	Thereafter	—
	Total	53,566
	Add: capital lease principal payments	1,336
	Total	54,902
	Less: current portion of long-term debt	(4,924		)
	Long-term debt, net of current portion	$	49,978

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Leases
	During the first quarter of 2008, the Company entered into a lease agreement and sublease agreement in order to consolidate the use and occupation of its then existing premises into two adjacent facilities, as described below. The Company also leases certain equipment and vehicles under operating leases which expire on various dates through 2018, and certain equipment under capital leases which expire on various dates through 2017.
	In February 2008, the Company entered into a sublease agreement (the “Sublease”), for office, engineering, and research and development space. The Sublease term commenced May 2008 and ends on January 31, 2016.
	The Company is obligated under the Sublease to pay base rent and certain operating costs and taxes for the building. Monthly base rent payable by the Company was approximately $80,500 during the first year of the Sublease, increasing annually at a fixed annual rate of 2.5% to approximately $93,500 per month in the final year of the Sublease. The Company’s rent was abated for months one through seven of the Sublease. At the sublease inception, the Company paid a security deposit in the amount of approximately $93,500.
	In March 2008, the Company entered into a lease agreement (the “Lease”) for additional office, engineering, research and development and warehouse and distribution space. The Lease term commenced on December 1, 2008 and ends on January 31, 2017. The Company is obligated under the Lease to pay base rent and certain operating costs and taxes for the building. The monthly base rent payable by the Company was approximately $73,500 during the first year of the Lease, increasing annually at a fixed annual rate of 3.0% to approximately $93,000 per month in the final year of the Lease. The Company’s rent was abated for the months two through eight of the term of the Lease in the amount of $38,480. At the lease inception, the Company paid a security deposit in the amount of approximately $293,200 consisting of cash and two letters of credit. Following the Company’s achievement of certain financial milestones, the lessor is obligated to return a portion of the security deposit to the Company. The lessor provided a tenant improvement allowance of $1.1 million to assist with the configuration of the facility to meet the Company’s business needs.
	Future minimum annual lease payments under the Company’s operating and capital leases are as follows (in thousands):
	Year ending December 31,	Operating		Capital
	2014	$	3,346	$	527
	2015	2,725		467
	2016	1,363		425
	2017	216		82
	2018	15		—
	Thereafter	—		—
		$	7,665	1,501
	Less: amount representing interest			(165		)
	Present value of minimum lease payments			1,336
	Current portion of capital leases			(439		)
	Capital leases, less current portion			$	897
	Rent expense under operating leases for the years ended December 31, 2013, 2012 and 2011 was $3.8 million, $3.7 million and $3.7 million, respectively.
	Litigation
	In 1998, Eurosurgical, a French company in the business of sales and marketing of spinal implants, entered into a distribution agreement for the United States, Mexico, Canada, India and Australia with Orthotec, LLC, a California company (“Orthotec”). In 2004, Orthotec sued Eurosurgical in connection with a contractual dispute and a final $9 million judgment was entered against Eurosurgical by a California court in 2006. In 2007, following a default judgment, a federal court in California declared Eurosurgical liable to Orthotec for $30 million in connection with an intellectual property dispute. In 2006, Eurosurgical’s European assets were ultimately acquired by Surgiview, SAS, or Surgiview, in a sale agreement, or the Partial Sale Agreement, approved by a French court. After this sale, Surgiview became a subsidiary of Scient’x in 2006. Orthotec attempted to recover on Eurosurgical’s obligations by filing a motion in a California court to add Surgiview to the judgment against Eurosurgical on theories including successor liability and fraudulent conveyance. In February 2007, the California court denied Orthotec’s motion, indicating that Orthotec had not carried its burdens of proof. Orthotec chose to not proceed with a further hearing in September 2007.
	In June 2004, HealthpointCapital (Luxembourg) I S.à.r.l. acquired a minority (33.1 percent) interest in Scient’x. In July 2005, Scient’x acquired an approximately 73 percent interest in Surgiview. At that time, HealthpointCapital Partners, L.P. (through a Luxembourg subsidiary) held a minority interest in Scient’x, which in turn held an interest in Surgiview, but HealthpointCapital Partners II, L.P. had no ownership interest in Scient’x or Surgiview. On November 21, 2007, more than a year after the Partial Sale Agreement was executed, HealthpointCapital Partners II, L.P. acquired majority ownership of Scient’x. In May 2008, after the acquisition of Scient’x by HealthpointCapital in 2007, Orthotec sued Scient’x, Surgiview, HealthpointCapital LLC and certain former directors of Scient’x (who also serve on the Company’s board) in a new action in California state court in which it sought (in addition to damages related to other causes of action and punitive damages related thereto) to have the defendants bear responsibility for the $39 million in judgments that had been assessed against Eurosurgical, which, together with interest is now greater than $70 million. On February 10, 2014 the jury reached a verdict in which Surgiview was found to have transferred assets for less than fair market value in connection with Surgiview’s purchase of certain assets of Eurosurgical, and to have interfered with certain contractual rights of Orthotec. Although a formal judgment has not yet been entered, the jury awarded monetary damages in the amount of $47.9 million, plus interest, against Surgiview related to various causes of action alleged by Orthotec.
	In addition, also in May 2008, a similar action was filed in New York against HealthpointCapital, HealthpointCapital LLC, HealthpointCapital Partners, L.P., HealthpointCapital Partners II, L.P., Scient’x and two former directors of Scient’x (who also serve on the Company’s board), in which Orthotec sought, in addition to damages related to other causes of action and punitive damages related thereto, to have the defendant’s bear responsibility for the $39 million in judgments that had been assessed against Eurosurgical, which, together with interest is now greater than $70 million.
	On March 15, 2014, the Company, Orthotec, LLC and certain other parties, including certain directors and affiliates of the Company, entered into a binding term sheet to settle all legal matters involving the Company and its directors and affiliates.  Pursuant to the term sheet, the Company has agreed to pay Orthotec $49 million in cash, with initial cash payments totaling $1.75 million by March 31, 2014 and an additional $15.75 million payment within 25 days of the Company closing a financing that would enable it to make such payment, but in no event no later than June 15, 2014.  The remaining $31.5 million will be paid to Orthotec in installments of $1.1 million paid quarterly, beginning in the fourth quarter of 2014. HealthpointCapital has agreed to contribute $5 million to the $49 million settlement amount. In addition, a 7% simple interest rate will accrue on the unpaid portion of the $31.5 million. All accrued interest is not payable until the $49 million is paid, and such accrued interest shall be paid in $1.1 million installments each quarter.  This settlement will result in mutual releases of all claims and the dismissal of all Orthotec-related litigation matters involving the Company, its directors and affiliates.
	On August 10, 2010, a purported securities class action complaint was filed in the United States District Court for the Southern District of California on behalf of all persons who purchased the Company's common stock between December 19, 2009 and August 5, 2010 against and certain of its directors and officers alleging violations of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. On February 17, 2011, an amended complaint was filed against the Company and certain of its directors and officers adding alleged violations of the Securities Act of 1933, as amended. HealthpointCapital, Jefferies & Company, Inc., Canaccord Adams, Inc., Cowen and Company, Inc., and Lazard Capital Markets LLC are also defendants in this action. The complaint alleges that the defendants made false or misleading statements, as well as failed to disclose material facts, about the Company’s business, financial condition, operations and prospects, particularly relating to the Scient’x transaction and our financial guidance following the closing of the acquisition. The complaint seeks unspecified monetary damages, attorneys’ fees, and other unspecified relief. The Company believe that the claims are without merit and it intends to vigorously defend itself against this complaint. However, the outcome of the litigation cannot be predicted at this time and any outcome that is adverse to the Company, regardless of who the defendant is, could have a significant adverse effect on its financial condition and results of operations.
	On August 25, 2010, an alleged shareholder of the Company’s filed a derivative lawsuit in the Superior Court of California, San Diego County, purporting to assert claims on behalf of the Company against all of its directors and certain of its officers and HealthpointCapital. Following the filing of this complaint, similar complaints were filed in the same court and in the U.S. District Court for the Southern District of California against the same defendants containing similar allegations. The complaint filed in federal court was dismissed by the plaintiff without prejudice in July 2011. The state court complaints have been consolidated into a single action and the Company has been named as a nominal defendant in the consolidated action. Each complaint alleges that the Company’s directors and certain of its officers breached their fiduciary duties to the Company related to the Scient’x transaction, and by making allegedly false statements that led to unjust enrichment of HealthpointCapital and certain of the Company’s directors. The complaints seek unspecified monetary damages and an order directing the Company to adopt certain measures purportedly designed to improve its corporate governance and internal procedures. On January 8, 2014, the parties reached an agreement in principle to resolve all claims in exchange for corporate governance reforms and payment of attorneys’ fees in the amount of $5.25 million, to be paid by the Company’s and HeathpointCapital’s respective insurance carriers. The Company believes the claims are without merit and, subject to final approval of any settlement,  intends to vigorously defend itself against these complaints. No assurances can be given as to the timing or outcome of this lawsuit.
	At December 31, 2013, the probable outcome of any of the aforementioned litigation matters cannot be determined nor can the Company estimate a range of potential loss. Accordingly, in accordance with the authoritative guidance on the evaluation of contingencies, the Company has not recorded an accrual related to these litigation matters. The Company is and may become involved in various other legal proceedings arising from its business activities. While management does not believe the ultimate disposition of these matters will have a material adverse impact on the Company’s consolidated results of operations, cash flows or financial position, litigation is inherently unpredictable, and depending on the nature and timing of these proceedings, an unfavorable resolution could materially affect the Company’s future consolidated results of operations, cash flows or financial position in a particular period.
	Royalties
	The Company has entered into various intellectual property agreements requiring the payment of royalties based on the sale of products that utilize such intellectual property. These royalties primarily relate to products sold by Alphatec Spine and are calculated either as a percentage of net sales or in one instance on a per-unit sold basis. Royalties are included on the accompanying consolidated statement of operations as a component of cost of revenues.

Redeemable_Preferred_Stock_and

Redeemable Preferred Stock and Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Redeemable Preferred Stock and Stockholders' Equity	'
	Redeemable Preferred Stock and Stockholders’ Equity
	Redeemable Preferred Stock
	The Company issued shares of redeemable preferred stock in connection with its initial public offering in June 2006. As of December 31, 2013, the redeemable preferred stock carrying value was $23.6 million and there were 20 million shares of redeemable preferred stock authorized. The redeemable preferred stock is not convertible into common stock but is redeemable at $9.00 per share, (i) upon the Company’s liquidation, dissolution or winding up, or the occurrence of certain mergers, consolidations or sales of all or substantially all of the Company’s assets, before any payment to the holders of the Company’s common stock, or (ii) at the Company’s option at any time. Holders of redeemable preferred stock are generally not entitled to vote on matters submitted to the stockholders, except with respect to certain matters that will affect them adversely as class, and are not entitled to receive dividends. The carrying value of the redeemable preferred stock was $7.11 per share at December 31, 2013 and 2012.
	The redeemable preferred stock is required to be shown in the Company’s financial statements separate from stockholders’ equity and any adjustments to its carrying value to its redemption value up to its redemption value of $9.00 per share will be reported as a dividend.
	Eclipse Advisors, LLC
	On May 8, 2012, the Company entered into an equity line of credit arrangement with Eclipse Advisors, LLC (“Eclipse”), which provides that, upon the terms and subject to the conditions set forth therein, the Company is entitled to sell and Eclipse is committed to purchase up to $25 million of shares of the Company’s common stock over a 24-month term (the “Investment Agreement). From time to time, and at the Company’s sole discretion, the Company may present Eclipse with put notices, to purchase the Company’s common stock in two tranches over a 31-day period (a “put period”) with each put period subject to being reduced by the Company based on a minimum threshold price of the Company’s common stock during the put period. The Company may not present Eclipse with a new put notice at any time there is an outstanding put notice.
	Once presented with a put notice, Eclipse is required to purchase: (i) 50% of the dollar amount of the shares specified in the put notice on the 16th day after the date of the put notice; and (ii) 50% of the dollar amount of the shares specified in the put notice on the 31st day after the date of the put notice. The price per share for the sale of such common stock for each of the two closings in a put period shall be 90% of the volume weighted average price for the Company’s common stock over the trading days that exist during the 15 days prior to such closing date. If the daily volume weighted average price of the Company’s common stock falls below a threshold price established by the Company on any trading day during a put period, the Company has the right to send a cancellation notice to Eclipse, which will reduce the Company’s obligation to sell the shares to Eclipse to no greater than 50% of the dollar amount set forth in the put notice.
	Upon execution of the Investment Agreement and as provided for therein, the Company issued Eclipse 231,045 shares of common stock representing a $500,000 commitment fee, determined by dividing $500,000 by the volume weighted average price for the Company’s common stock for the five trading days preceding the effective date of the Investment Agreement. The Company has not sold any shares to Eclipse under the Investment Agreement.

Stock_Benefit_Plans_and_StockB

Stock Benefit Plans and Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Benefit Plans and Stock-Based Compensation	'
	Stock Benefit Plans and Stock-Based Compensation
	In 2005, the Company adopted its 2005 Employee, Director, and Consultant Stock Plan (the “2005 Plan”). The 2005 Plan allows for the grant of options and restricted stock awards to employees, directors, and consultants of the Company. The 2005 Plan has 14,200,000 shares of common stock reserved for issuance. The Board of Directors determines the terms of the restricted stock and the term of each option, option price, number of shares for which each option is granted, whether restrictions will be imposed on the shares subject to options, and the rate at which each option is exercisable. Options granted under the 2005 Plan expire no later than 10 years  from the date of grant (5 years for incentive stock options granted to holders of more than 10% of the Company’s voting stock). Options generally vest over a four year period and may be immediately exercisable upon a change of control of the Company. The exercise price of incentive stock options may not be less than 100% of the fair value of the Company’s common stock on the date of grant. The exercise price of any option granted to a 10% stockholder may be no less than 110% of the fair value of the Company’s common stock on the date of grant. At December 31, 2013, approximately 3,200,000 shares of common stock remained available for issuance under the 2005 Plan.
	Stock Options
	A summary of the Company’s stock option activity under the 2005 Plan and related information is as follows (in thousands, except as indicated and per share data):
		Shares		Weighted		Weighted	Aggregate
				average		average	intrinsic
				exercise		remaining	value
				price		contractual
						term
						(in years)
	Outstanding at December 31, 2012	4,920		$	2.51	8.03	$	64
	Granted	4,541		$	1.9	—	—
	Exercised	(6	)	$	1.54	—	—
	Forfeited	(1,645	)	$	2.12	—	—
	Outstanding at December 31, 2013	7,810		$	2.23	7.59	$	753
	Options vested and exercisable at December 31, 2013	2,640		$	2.79	6.1	$	125
	Options vested and expected to vest at December 31, 2013	7,218		$	2.26	7.51	$	679
	The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2013, 2012 and 2011 was $1.09, $1.10 and $1.48, respectively. The aggregate intrinsic value of options at December 31, 2013 is based on the Company’s closing stock price on that date of $2.01 per share.
	As of December 31, 2013, there was $3.3 million of unrecognized compensation expense for stock options and awards which is expected to be recognized on a straight-line basis over a weighted average period of approximately 2.7 years. The total intrinsic value of options exercised was immaterial for the years ended December 31, 2013 and 2012. The total intrinsic value of options exercised for the year ended December 31, 2011 was $0.1 million.
	On November 19, 2012, the Company commenced a stock option exchange offer for its U.S. employees. The options eligible for exchange had an exercise price equal to or greater than $2.85. The exercise price of the exchanged options was the higher of 115% of the closing price of the Company’s common stock on the exchange date and $2.00. The exchange offer occurred on December 19, 2012 and the exercise price for the exchanged options was $2.05. A total of 1,109,604 options to purchase shares of the Company’s common stock were exchanged. Many of the outstanding options were either partially or fully vested. The exchanged options will be unvested upon issuance and will vest over 3 years, with one-third of each option vesting on the first anniversary date and the remaining portion of each option vesting in equal quarterly installments over the eight quarters following the first anniversary date.
	Restricted Stock Awards
	The following table summarizes information about the restricted stock awards activity (in thousands, except as indicated and per share data):
		Shares		Weighted		Weighted
				average		average
				grant		remaining
				date fair		recognition
				value		period
						(in years)
	Unvested at December 31, 2012	877		$	1.81	1.49
	Awarded	375		$	1.97
	Vested	(375	)	$	1.84
	Forfeited	(70	)	$	1.65
	Unvested at December 31, 2013	807		$	1.88	2.3
	The weighted average fair value per share of awards granted during the years ended December 31, 2013, 2012 and 2011 was $1.97, $1.57 and $2.61, respectively.
	Warrants
	In March 2012, the Company entered into a consulting agreement with a third-party entity and pursuant to such consulting agreement, the Company issued a warrant to the consultant to purchase an aggregate of 500,000 shares of the Company’s common stock at an exercise price of $2.50 per share. The warrant expires on March 1, 2015 and is 100% vested on December 31, 2013.
	In December 2011, in connection with the third amendment to the SVB Credit Facility, finance charges totaling $0.2 million were waived in exchange for the issuance to SVB of warrants to purchase 93,750 shares of the Company’s common stock. The warrants are immediately exercisable, can be exercised through a cashless exercise, have an exercise price of $1.60 per share and have a ten year term. The Company recorded the value of the warrants of $0.1 million as a debt discount. The value of the warrants was determined on the date of grant using the Black-Scholes-Merton valuation method with the following assumptions: risk free interest rate of 1.23%, volatility of 57.4%, a ten year term and no dividend yield.
	Elite Medical Holdings and Pac 3 Surgical Products Agreement
	In October 2013, the Company entered into a three-year collaboration agreement with a third party to provide consultation services to assist the Company in the development of its products and its products in development. Under the terms of the collaboration agreement, the Company will gain exclusive rights to the use of all intellectual property developed by the collaborators. The Company will make three annual payments to the collaborator as sole consideration for services provided, totaling an aggregate of up to $8 million, paid in common stock of Alphatec Holdings at a per share price of $1.95, which was equal to the average NASDAQ closing price of the common stock on the five days leading up to and including the date of signing the collaboration agreement. The actual number of shares issued each year will be determined by the fair market value of the services provided over the prior 12 months. In 2013, the Company issued 128,571 shares of its common stock under this agreement.
	Media Advertising Agreement
	In 2012, the Company entered into consulting agreements with a third-party entity for marketing and advertising services. In connection with these agreements the Company paid the consultant $0.2 million, issued 500,000 registered shares of the Company’s common stock and issued 352,000 unregistered shares of the Company’s common stock. In May 2013, the Company entered into an additional consulting agreement with a third-party entity for marketing and advertising services. In connection with this agreement the Company paid the consultant total cash consideration of $0.2 million and issued 225,000 restricted shares of the Company’s common stock. The Company recorded total stock compensation related to these agreements during the years ended December 31, 2013 and 2012 of $0.7 million and $1.1 million, respectively.
	Common Stock Reserved for Future Issuance
	Common stock reserved for future issuance consists of the following (in thousands):
		31-Dec-13
	Stock options outstanding	7,810
	Awards outstanding	807
	Warrants outstanding	594
	Authorized for future grant under 2005 Plan	3,166
		12,377

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The components of the pretax loss from operations for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands):
		Year Ended December 31,
		2013				2012				2011
	U.S. Domestic	$	(9,264	)		$	(3,310	)		$	(14,400	)
	Foreign	(69,784		)		(13,308		)		(12,288		)
	Pretax loss from operations	$	(79,048	)		$	(16,618	)		$	(26,688	)
	The components of the (benefit) provision for income taxes are presented in the following table (in thousands):
		Year Ended December 31,
		2013				2012				2011
	Current:
	Federal	$	(21	)		$	107			$	4
	State	186				24				222
	Foreign	2,525				2,083				(388		)
	Total current provision (benefit)	2,690				2,214				(162		)
	Deferred:
	Federal	229				137				163
	State	15				29				8
	Foreign	245				(3,539		)		(4,516		)
	Total deferred provision (benefit)	489				(3,373		)		(4,345		)
	Total provision (benefit)	$	3,179			$	(1,159	)		$	(4,507	)
	The (benefit) provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to pretax income as a result of the following differences:
		December 31,
		2013			2012			2011
	Federal statutory rate	(35.0	)%		(35.0	)%		(35.0	)%
	Adjustments for tax effects of:
	State taxes, net	(0.1	)%		(0.0	)%		(0.7	)%
	Stock-based compensation	0.5	%		(0.5	)%		1.8	%
	Foreign taxes	1.1	%		(0.1	)%		3.6	%
	Tax credits	(0.4	)%		(0.7	)%		(1.2	)%
	Deemed foreign dividend	—	%		0.2	%		10.3	%
	Intercompany debt forgiveness and other permanent adjustments	9.5	%		5	%		0.8	%
	Tax rate adjustment	0.2	%		0.7	%		(0.5	)%
	Uncertain tax positions	2.7	%		14.9	%		(1.5	)%
	Other	(0.4	)%		3.3	%		(3.1	)%
	Valuation allowance	25.9	%		5.2	%		8.7	%
		4	%		(7.0	)%		(16.8	)%
	The 2013 provision for income taxes primarily consists of an increase in unrecognized tax benefits associated with the European operations, tax expense related to non-income based state tax in the U.S. and current year income in Japan and Brazil, and an increase in the deferred tax liability related to tax-deductible goodwill in the U.S.
	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows (in thousands):
		December 31,
		2013				2012
	Deferred tax assets:
	Allowances and reserves	$	816			$	1,088
	Accrued expenses	3,685				648
	Inventory reserves	7,549				7,839
	Net operating loss carryforwards	26,497				28,786
	Property and equipment	1,171				—
	Stock-based compensation	2,769				1,866
	Legal settlement	17,998				4,156
	Income tax credit carryforwards	1,800				1,276
		62,285				45,659
	Valuation allowance	(56,690		)		(36,031		)
	Total deferred tax assets, net of valuation allowance	5,595				9,628
	Deferred tax liabilities:
	Property and equipment	—				926
	Intangible assets	4,806				6,910
	Goodwill	1,256				1,011
	Total deferred tax liabilities	6,062				8,847
	Net deferred tax assets (liabilities)	$	(467	)		$	781
	The realization of deferred tax assets may be dependent on the Company’s ability to generate sufficient income in future years in the associated jurisdiction to which the deferred tax assets relate. The Company considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.  Based on the review of all positive and negative evidence, including a three year cumulative pre-tax loss, it was concluded that a full valuation allowance of $56.7 million should be recorded against all U.S. and European deferred tax assets at December  31, 2013.  During 2012, it was determined that the Company was more-likely-than-not to realize its Japanese deferred tax assets.  The Company removed the valuation allowance on the Japanese deferred tax assets and recognized a tax benefit of $1.4 million in 2012.  In the event that the Company were to determine that it would not be able to realize all or part of its Japanese deferred tax assets in the future, it would increase the valuation allowance and recognize a corresponding tax provision in the period in which it made such a determination.  Likewise, if the Company later determines that it is more-likely-than-not to realize all or a portion of the U.S. or European deferred tax assets, it would reverse the previously provided valuation allowance.
	At December 31, 2013, the Company has unrecognized tax benefits of $7.8 million of which $7.2 million will affect the effective tax rate if recognized when the Company no longer has a valuation allowance offsetting its deferred tax assets.
	The following table summarizes the changes to unrecognized tax benefits for the years ended December 31, 2013, 2012 and 2011 (in thousands):
	Balance at December 31, 2010	$	4,421
Additions based on tax positions related to the prior year	73
Additions based on tax positions related to the current year	399
Reductions as a result of positions taken	(59		)
Reductions as a result of lapse of applicable statute of limitations	(649		)
Additions as a result of foreign exchange rates and other	12
Balance at December 31, 2011	$	4,197
Additions based on tax positions related to the prior year	987
Additions based on tax positions related to the current year	743
Reductions as a result of lapse of applicable statute of limitations	(58		)
Additions as a result of foreign exchange rates and other	28
Balance at December 31, 2012	$	5,897
Additions based on tax positions related to the prior year	221
Additions based on tax positions related to the current year	1,664
Reductions as a result of lapse of applicable statute of limitations	(20		)
Additions as a result of foreign exchange rates and other	73
Balance at December 31, 2013	$	7,835
The Company believes it is reasonably possible it will not materially reduce its unrecognized tax benefits within the next 12 months.
The Company and its subsidiaries are subject to federal income tax as well as income tax of multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to income tax examination by tax authorities in major jurisdictions for years prior to 2008. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where NOLs and tax credits were generated and carried forward, and make adjustments up to the amount of the carryforwards. The Company is not currently under examination by the IRS, foreign or state and local tax authorities.
During 2013, the IRS completed its income tax examination of the 2011 tax year, which resulted in no material adjustments.
The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. As of December 31, 2013, accrued interest and penalties were $1.3 million and this amount primarily relates to the uncertain tax positions of the Scient’x operations and state positions. During 2013, there was an increase of $0.9 million in the accrued interest and penalties related to the uncertain tax positions of the Scient’x operations.
At December 31, 2013, the Company had federal and state net operating loss carryforwards of $39.8 million and $52.9 million, respectively, expiring at various dates through 2033. At December 31, 2013, the Company had federal and state research and development tax credits of $2.7 million and $2.3 million, respectively. The federal research and development tax credits expire at various dates through 2033, while the state credits do not expire. The Company had foreign net operating loss carryforwards of $41.0 million beginning to expire in 2018. Utilization of the net operating loss and tax credit carryforwards may become subject to annual limitations due to ownership change limitations that could occur in the future as provided by Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state and foreign provisions. These ownership changes may limit the amount of the net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income. An ownership change occurred during June 2006 in connection with the initial public offering. The annual limitation as a result of that ownership change did not result in the loss or substantial limitation of net operating loss or tax credit carryforwards. There have been no subsequent ownership changes through December 31, 2013.
The Company does not record U.S. income taxes on the undistributed earnings of its foreign subsidiaries based upon the Company’s intention to permanently reinvest undistributed earnings to ensure sufficient working capital and further expansion of existing operations outside the United States. The undistributed earnings of the foreign subsidiaries as of December 31, 2013 are immaterial. In the event the Company is required to repatriate funds from outside of the United States, such repatriation would be subject to local laws, customs, and tax consequences.

Segment_and_Geographical_Infor

Segment and Geographical Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment and Geographical Information	'
	Segment and Geographical Information
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one reportable business segment.
	During the years ended December 31, 2013, 2012 and 2011, the Company operated in two geographic regions, the U.S. and International which consists of locations outside of the U.S. In the International geographic location, sales in Japan for the years ended December 31, 2013, 2012 and 2011 totaled $28.0 million, $28.6 million and $23.9 million, respectively, which represented greater than 10 percent of the Company’s consolidated revenues for the years then ended December. For the years ended December 31, 2013, 2012 and 2011, sales in other individual countries included in International did not exceed 10 percent of consolidated revenues.
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Year Ended December 31,
		2013		2012		2011
	United States	$	134,951	$	130,476	$	133,824
	International	69,773		65,802		63,887
	Total consolidated revenues	$	204,724	$	196,278	$	197,711
	Total assets by region were as follows (in thousands):
		December 31,
		2013		2012
	United States	$	196,383	$	213,912
	International	169,247		168,215
	Total consolidated assets	$	365,630	$	382,127

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	For the years ended December 31, 2013, 2012 and 2011, the Company incurred costs of $0.2 million, $0.2 million and $0.1 million, respectively, to Foster Management Company and HealthpointCapital, LLC for travel and administrative expenses, including the use of Foster Management Company’s airplane. Foster Management Company is an entity owned by John H. Foster, a member of the Company’s board of directors. John H. Foster is a significant equity holder of HealthpointCapital, LLC, an affiliate of HealthpointCapital Partners, L.P. and HealthpointCapital Partners II, L.P., which are the Company’s principal stockholders.
	Indemnification Agreements
	The Company has entered into indemnification agreements with certain of its directors which are named defendants in the New York matter (See Note 7 - Commitments and Contingencies - Litigation). The indemnification agreements require the Company to indemnify these individuals to the fullest extent permitted by applicable law and to advance expenses incurred by them in connection with any proceeding against them with respect to which they may be entitled to indemnification by the Company. For the years ended December 31, 2013 and 2012, the Company paid approximately $1.7 million and $2.6 million, respectively, in connection with the indemnification obligations of Scient’x and Surgiview, all of which was related to the Orthotec matter. (See Note 7)

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Retirement Plan	'
	Retirement Plan
	The Company maintains an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Under the savings plan, participating employees may contribute a portion of their pre-tax earnings, up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make matching contributions into the savings plan at its sole discretion of up to 4% of each individual’s compensation. Match amounts are vested after one year of service. The Company’s total contributions to the 401(k) plan were $0.6 million, $0.5 million and $0.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.

Restructuring_Activities

Restructuring Activities	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring Activities	'
	Restructuring Activities
	On September 16, 2013, the Company announced that Scient'x has begun a process to significantly restructure its business operations in France in an effort to improve operating efficiencies and rationalize its cost structure. The restructuring includes an expected reduction in Scient'x's workforce and closing of the manufacturing facilities in France. The Company estimates that it will record total costs, including employee severance, social plan benefits and related taxes, facility closing costs, manufacturing transfer costs, and contract termination costs of approximately $12 million associated with this restructuring. In accordance with ASC Topic 420, Accounting for Costs Associated with Exit or Disposal Activities and ASC Topic 712, Non retirement Postemployment Benefits, the Company has recorded a restructuring charge accrual in accrued expenses of $9.2 million within the consolidated balance sheets as of December 31, 2013 and restructuring expenses of $9.7 million within the consolidated statements of operations for the year ending December 31, 2013. The Company estimates that it will record severance and benefits of approximately $9.7 million and facility closing and other restructuring costs of approximately $2.2 million. The Company expects to complete all the activities associated with the restructuring activities by the end of the second quarter of 2014, a substantial portion of which will be paid by then.
	In connection with the restructuring plan, the Company modified its estimate of inventory and instrument net book value at its Scient'x entities based on revised global demand. The Company recorded an additional inventory reserve of $4.9 million in the year ended December 31, 2013 included in cost of goods sold within the consolidated statements of operations.
	Below is a table of the movement (in thousands):
		Expensed		Paid and			Accrued		Total		Remaining
		31-Dec-13		Other			31-Dec-13		Costs		Costs
	Social plan	$	8,893	$	(84	)	$	8,809	$	9,705	$	535
	French non-social plan costs	210		(210		)	—		2,162		2,162
	US booked social cost	361		—			361		—		—
	US costs other	201		(201		)	—		—		—
	Total	$	9,665	$	(495	)	$	9,170	$	11,867	$	2,697

Cross_Medical

Cross Medical	12 Months Ended
	Dec. 31, 2013
Cross Medical [Abstract]	'
Cross Medical	'
	Cross Medical
	On February 12, 2010, a complaint was filed in the U.S. District Court for the Central District of California, by Cross Medical Products, LLC, or Cross, (a subsidiary of Biomet), Cross Medical Products, LLC v. Alphatec Spine, Inc., Case No. 8:10-cv-176-MRP -MLG, alleging that we breached a patent license agreement with Cross by failing to make certain royalty payments allegedly due under the agreement. Cross was seeking payment of prior royalties allegedly due from the Company’s sales of polyaxial screws and an order from the court regarding payment of future royalties by us. In its complaint, Cross alleged a material amount of damages were due to it as a result of our alleged breach of the patent license agreement.
	In January 2011, we filed a complaint in the U.S. District Court for the Southern District of California against Biomet, Inc., or Biomet, alleging that Biomet’s TPS-TL products infringe one of our patents. On December 30, 2011, we reached a global settlement agreement of the pending lawsuits with Biomet and Cross. Under the terms of the settlement, all parties obtained a release of all claims that were the subject of the disputes. No party has admitted liability in connection with the settlement. The settlement also includes an amendment to the April 23, 2003 License Agreement.
	As part of the settlement, we agreed to pay Cross an initial payment of $5 million, which payment was made in January 2012. In addition to the initial payment, we will make thirteen quarterly payments of $1 million beginning on August 1, 2012, with each subsequent payment due three months thereafter until the final payment is made in August 2015. The remaining cash obligations totaling $7 million will be paid as follows: $4 million in 2014 and $3 million in 2015. In addition, pursuant to the settlement, the parties have exchanged covenants not to sue for patent infringement with respect to products that each respective company had on the market as of December 30, 2011.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data (Unaudited)	'
	Quarterly Financial Data (Unaudited)
	The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for fiscal 2013 and 2012 are as follows (in thousands, except per share data):
		Year ended December 31, 2013
		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
	Selected quarterly financial data:
	Revenue	$	50,443		$	51,020		$	50,196		$	53,065
	Gross profit	32,742			32,093			24,232			35,255
	Total operating expenses	34,100			34,992			37,406			91,257
	Net loss	(2,649		)	(4,661		)	(14,510		)	(60,407		)
	Basic and diluted net loss per common share (1)	(0.03		)	(0.05		)	(0.15		)	(0.62		)
		Year ended December 31, 2012
		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
	Selected quarterly financial data:
	Revenue	$	48,461		$	48,235		$	46,839		$	52,743
	Gross profit	31,819			30,196			29,633			32,120
	Total operating expenses	31,944			33,947			31,606			36,108
	Net loss	(1,261		)	(6,374		)	(2,469		)	(5,355		)
	Basic and diluted net loss per common share (1)	(0.01		)	(0.07		)	(0.03		)	(0.06		)
	-1	Basic and diluted net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal the total for the year.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	Orthotec LLC, Litigation Settlement
	On March 15, 2014, the Company, Orthotec and certain other parties, including certain directors and affiliates of the Company entered into a binding term sheet to settle the pending litigation in the Orthotec, LLC vs. Surgical S.A.S. legal matter (See Note 7) and all other litigation matters related to the Company and its directors and affiliates. Pursuant to the term sheet, the Company has agreed to pay Orthotec $49 million in cash payments totaling $1.75 million by March 31, 2014 and an additional $15.75 million payment due by within 25 days of the closing of the Facility Agreement (as defined below). The remaining $31.5 million will be paid to Orthotec in 28 quarterly installments of $1.1 million beginning in the fourth quarter of 2014. HealthpointCapital has agreed to contribute $5 million to the $49 million settlement amount. In addition, a 7% simple interest rate will accrue on the unpaid portion of the $31.5 million which will be paid in $1.1 million quarterly payments after the $49 million settlement amount is paid. The Company anticipates to fund a portion of the 2014 payment obligations with proceeds from the Facility Agreement described below. The $49 million settlement was accrued at its present value of $46.2 million as of December 31, 2013.
	Deerfield Facility Agreement
	On March 17, 2014, the Company entered into a facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Special SituationsInternational Master Fund, L.P. (collectively “Deerfield”), pursuant to which Deerfield agreed to loan the Company up to $50 million, subject to the terms and conditions set forth in the Facility Agreement. Under the terms of the Facility Agreement, the Company has the option, but is not required, upon certain conditions to draw the entire amount available under the Facility Agreement, at any time until January 30, 2015 (the “Draw Period”), provided that the initial draw be used for a portion of the payments made in connection with the Orthotec settlement described above. Following such initial draw down, the Company may draw down additional amounts under the Facility Agreement up to an aggregate $15 million for working capital or general corporate purposes in $2.5 million increments until the end of the Draw Period. In addition, in the event the Litigation Satisfaction has not occurred prior to December 15, 2014, the Company may request no later than January 30, 2015 a draw of the entire amount available under the Facility Agreement; provided that such amount will remain in a special deposit account until the Litigation Satisfaction occurs. The Company has agreed to pay Deerfield, upon each disbursement of funds under the Facility Agreement, a transaction fee equal to 2.5% of the principal amount of the funds disbursed. Amounts borrowed under the Facility Agreement bear interest at a rate of 8.75% per annum and are payable on the third, fourth and fifth anniversary date of the first amount borrowed under the Facility Agreement, with the final payment due no later than December 15, 2019.
	The Facility Agreement also contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on the ability of the Company and its subsidiaries to incur additional indebtedness or liens on its assets, except as permitted under the Facility Agreement. As security for our repayment of our obligations under the Facility Agreement, we granted to Deerfield a security interest in substantially all of our property and interests in property that are subordinated to the security interest granted under the Amended Credit Facility.
	In connection with the execution of the Facility Agreement, on March 17, 2014, the Company issued to Deerfield warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock immediately exercisable at an exercise price initially equal to $1.39 (the “Initial Warrants”) expiring on March 17, 2020. The number of shares of common stock into which the Warrants are exercisable and the exercise price will be adjusted to reflect any stock splits, payment of stock dividends, recapitalizations, reclassifications or other similar adjustments in the number of outstanding shares of the Company’s common stock.
	Each disbursement borrowing under the Facility Agreement shall be accompanied by the issuance to Deerfield of warrants to purchase up to 10,000,000 shares of the Company’s common stock, at an exercise price equal to the lesser of the Initial Warrant exercise price or the average daily volume weighted average price per share of the Company’s common stock for the 15 days following the request for borrowing (the “Draw Warrants”). The number of Draw Warrants issued for each draw will be in proportion to the amount of draw compared to the total $50 million facility. The number of shares of common stock into which a warrant is exercisable and the exercise price of any warrant will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock. The warrants have the same dividend rights to the same extent as if the warrants were exercised into shares of common stock.
	On March 19, 2014, the Company made an initial draw under the Facility Agreement and received net proceeds of $19.5 million to fund its 2014 Orthotec settlement payment obligations. In connection with this borrowing, the Company issued 4,000,000 Draw Warrants at an exercise price of $1.39.
	MidCap Amendment
	On March 17, 2014, the Company entered into a first amendment to the Amended Credit Facility (the “First Amendment”) with MidCap. Under the First Amendment, MidCap gave the Company its consent to enter into the Facility Agreement and make settlement payments in connection with the Orthotec Litigation. The First Amendment also added a total leverage ratio financial covenant.

SCHEDULE_IIVALUATION_AND_QUALI

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	'
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
		Allowance			Reserve for
		for			Excess and
		Doubtful			Obsolete
		Accounts (1)			Inventories (2)
		(In thousands)
	Balance at December 31, 2010	$	1,154		$	11,030
	Provision	1,094			4,564
	Write-offs and recoveries, net	(1,193		)	(2,420		)
	Balance at December 31, 2011	1,055			13,174
	Provision	859			6,658
	Write-offs and recoveries, net	(840		)	(2,610		)
	Balance at December 31, 2012	1,074			17,222
	Provision	404			11,652
	Write-offs and recoveries, net	(430		)	(4,928		)
	Balance at December 31, 2013	$	1,048		$	23,946
	-1	The provision is included in selling expenses.
	-2	The provision is included in cost of revenues.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the Company’s consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Concentrations of Credit Risk and Significant Customers	'
	Concentrations of Credit Risk and Significant Customers
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and accounts receivable. The Company limits its exposure to credit loss by depositing its cash and cash equivalents with established financial institutions. As of December 31, 2013 a substantial portion of the Company’s available cash funds is in business accounts. Although the Company deposits its cash and cash equivalents with multiple financial institutions, its deposits, at times, may exceed federally insured limits.
	The Company’s customers are primarily hospitals, surgical centers and distributors and no single customer represented greater than 10 percent of consolidated revenues for any of the periods presented. Credit to customers is granted based on an analysis of the customers’ credit worthiness and credit losses have not been significant.
Revenue Recognition	'
	Revenue Recognition
	The Company derives its revenues primarily from the sale of spinal surgery implants used in the treatment of spine disorders. The Company sells its products primarily through its direct sales force and independent distributors. Revenue is recognized when all four of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured. In addition, the Company accounts for revenue under provisions which sets forth guidelines for the timing of revenue recognition based upon factors such as passage of title, installation, payment and customer acceptance.
	The Company’s revenue from sales of spinal and other surgical implants is recognized upon receipt of written acknowledgement that the product has been used in a surgical procedure or upon shipment to third-party customers who immediately accept title to such implant.
Deferred Revenues	'
	Deferred revenues consist of products sold to distributors with payment terms greater than the Company’s customary business terms due to lack of credit history or because the distributor is operating in a new market in which the Company has no prior experience. The Company defers the recognition of revenue until payments become due and cash is received from these distributors.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable are presented net of allowance for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for a portion of receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices not specifically reviewed. In determining the provision for invoices not specifically reviewed, the Company analyzes historical collection experience. If the historical data used to calculate the allowance provided for doubtful accounts does not reflect the Company’s future ability to collect outstanding receivables or if the financial condition of customers were to deteriorate, resulting in impairment of their ability to make payments, an increase in the provision for doubtful accounts may be required.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market, with cost primarily determined under the first-in, first-out method. The Company reviews the components of inventory on a periodic basis for excess, obsolete and impaired inventory, and records a reserve for the identified items. The Company calculates an inventory reserve for estimated excess and obsolete inventory based upon historical turnover and assumptions about future demand for its products and market conditions. The Company’s biologics inventories have an expiration based on shelf life and are subject to demand fluctuations based on the availability and demand for alternative implant products. The Company’s estimates and assumptions for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the reserve for excess and obsolete inventory result in a corresponding increase to cost of revenues and establish a new cost basis for the part.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally ranging from three to seven years. Leasehold improvements and assets acquired under capital leases are amortized over the shorter of their useful lives or the terms of the related leases.
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	The Company accounts for goodwill and other intangible assets in accordance with provisions which require that goodwill and other identifiable intangible assets with indefinite useful lives be tested for impairment at least annually. The Company tests goodwill and intangible assets for impairment in December of each year, or more frequently if events and circumstances warrant. These assets are impaired if the Company determines that their carrying values may not be recoverable based on an assessment of certain events or changes in circumstances. If the assets are considered to be impaired, the Company recognizes the amount by which the carrying value of the assets exceeds the fair value of the assets as an impairment loss. During the year ended December 31, 2013, the Company decided that it would not continue to market an adult stem cell product sold under the Company's private label name of Puregen. The Company also decided that it would no longer actively market two additional products. The Company expensed $1.3 million as impairment charges in cost of goods sold in the year ended December 31, 2013 for the write-off of intangible assets related to these products.
	The Company estimated the fair value in step one of the goodwill impairment test based on a combination of the income approach which included discounted cash flows as well as a market approach that utilized the Company’s market information. The income approach fair value measurements are categorized within Level 3 of the fair value hierarchy. The Company’s discounted cash flows required management judgment with respect to forecasted sales, launch of new products, gross margin, selling, general and administrative expenses, capital expenditures and the selection and use of an appropriate discount rate and terminal rate. For purposes of calculating the discounted cash flows, the Company used estimated revenue growth rates averaging between 4% and 12% for the discrete forecast period. Cash flows beyond the discrete forecasts were estimated using a terminal value calculation, which incorporated historical and forecasted financial trends and considered long-term earnings growth rates for publicly traded peer companies. Future cash flows were then discounted to present value at a discount rate of 12%, and terminal value growth rate of 4%. Publicly available information regarding comparable market capitalization was also considered in assessing the reasonableness of the Company’s fair value. The Company’s assessment resulted in a fair value that was greater than the Company’s carrying value at December 31, 2013. In accordance with the authoritative literature, the second step of the impairment test was not required to be performed and thus no impairment of goodwill was recorded as of December 31, 2013.
	Significant management judgment is required in the forecast of future operating results that are used in the Company’s impairment analysis. The estimates the Company used are consistent with the plans and estimates that it uses to manage its business. Significant assumptions utilized in the Company’s income approach model included the growth rate of sales for recently introduced products and the introduction of anticipated new products similar to its historical growth rates. Another important assumption involved in forecasted sales is the projected mix of higher margin U.S. based sales and lower margin non-U.S. based sales. Additionally, the Company has projected an improvement in its gross margin, similar to its historical improvement in gross margins, as a result of its forecasted mix in U.S. sales versus non-U.S. based sales and lower manufacturing cost per unit based on the increase in forecasted volume to absorb applied overhead over the next ten years. Although the Company believes its underlying assumptions supporting this assessment are reasonable, if the Company’s forecasted sales, mix of product sales, growth rates of recently introduced new products, timing of and growth rates of new product introductions, gross margin, selling, general and administrative expenses, or the discount rate vary from its forecasts, the Company could be exposed to material impairment charges in the future. Additionally, if the Company’s stock price decreases significantly from the closing price on December 31, 2013, the Company may be required to perform an interim analysis in 2014 that could result in an impairment charge.
	The accounting provisions also require that intangible assets with definite useful lives be amortized over their respective estimated useful lives and reviewed for indicators of impairment. The Company is amortizing its intangible assets, other than goodwill, on a straight-line basis over a one to fifteen-year period.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company assesses potential impairment to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the carrying amount of the long-lived assets is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results.
Foreign Currency	'
	Foreign Currency
	The Company’s results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. The Company’s primary functional currency is the U.S. dollar, while the functional currency of the Company’s Japanese subsidiary is the Japanese Yen, the Hong Kong subsidiary is the Hong Kong dollar and the functional currency of the Company’s European operations is the Euro. Assets and liabilities denominated in foreign currencies are translated at the rate of exchange on the balance sheet date. Revenues and expenses are translated using the average exchange rate for the period. Net gains and losses resulting from the translation of foreign financial statements are recorded as accumulated other comprehensive income (loss) in stockholders’ equity. Net foreign currency gains or (losses) resulting from transactions in currencies other than the functional currencies are included in other income (expense), net in the accompanying consolidated statements of operations.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying value of accounts receivable, foreign cash accounts, prepaid expenses, other current assets, accounts payable, accrued expenses, and current portion of debt are considered to be representative of their respective fair values because of the short- term nature of those instruments. Based on the borrowing rates currently available to the Company for loans with similar terms, management believes the fair value of notes payable, capital leases and other long-term debt approximates their carrying values.
	The Company measures its fair value of financial instruments in accordance with the established framework for fair value using “levels” which are defined as follows: Level 1 fair value is determined from observable, quoted prices in active markets for identical assets or liabilities. Level 2 fair value is determined from quoted prices for similar items in active markets or quoted prices for identical or similar items in markets that are not active. Level 3 fair value is determined using the entity’s own assumptions about the inputs that market participants would use in pricing an asset or liability.
	The Company reassesses the fair value of contingent consideration of $3.8 million to be settled in cash related to acquisitions on a quarterly basis using the present value of future royalty payments due. This is a Level 3 measurement. Significant assumptions used in the measurement include estimates of the royalty payments due.
Research and Development	'
	Research and Development
	Research and development expense consists of costs associated with the design, development, testing, and enhancement of the Company’s products. Research and development costs also include salaries and related employee benefits, research-related overhead expenses, fees paid to external service providers, and costs associated with the Company’s Scientific Advisory Board and Executive Surgeon Panels. Research and development costs are expensed as incurred.
In-Process Research and Development	'
	In-Process Research and Development
	In-process research and development (“IPR&D”) consists of acquired research and development assets that are not part of an acquisition of a business and were not technologically feasible on the date the Company acquired them and had no alternative future use at that date or IPR&D assets acquired in a business acquisition that are determined to have no alternative future use. The Company expects all acquired IPR&D will reach technological feasibility, but there can be no assurance that commercial viability of these products will ever be achieved. The nature of the efforts to develop the acquired technologies into commercially viable products consists principally of planning, designing, developing and testing products in order to obtain regulatory approvals. If commercial viability were not achieved, the Company would likely look to other alternatives to provide these products. Until the technological feasibility of the acquired research and development assets are established, the Company expenses these costs.
Leases	'
	Leases
	The Company leases its facilities and certain equipment and vehicles under operating leases, and certain equipment under capital leases. For facility leases that contain rent escalation or rent concession provisions, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease. The Company records the difference between the rent paid and the straight-line rent as a deferred rent liability in the accompanying consolidated balance sheets.
Product Shipment Cost	'
	Product Shipment Cost
	Product shipment costs are included in sales and marketing expense in the accompanying consolidated statements of operations.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company accounts for stock-based compensation under provisions which require that share-based payment transactions with employees be recognized in the financial statements based on their fair value and recognized as compensation expense over the vesting period. The amount of expense recognized during the period is affected by subjective assumptions, including: estimates of the Company’s future volatility, the expected term for its stock options, the number of options expected to ultimately vest, and the timing of vesting for the Company’s share-based awards.
	The Company uses a Black-Scholes-Merton option-pricing model to estimate the fair value of its stock option awards. The calculation of the fair value of the awards using the Black-Scholes-Merton option-pricing model is affected by the Company’s stock price on the date of grant as well as assumptions regarding the following:
	•	Estimated volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate each year during the expected life of the award. The Company’s estimated volatility through December 31, 2013 was based on a weighted-average volatility of its actual historical volatility over a period equal to the expected life of the awards.
	•	The expected term represents the period of time that awards granted are expected to be outstanding. Through December 31, 2013, the Company calculated the expected term using a weighted-average term based on historical exercise patterns and the term from option date to full exercise for the options granted within the specified date range.
	•	The risk-free interest rate is based on the yield curve of a zero-coupon U.S. Treasury bond on the date the stock option award is granted with a maturity equal to the expected term of the stock option award.
	•	The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future.
	The Company used historical data to estimate the number of future stock option forfeitures. Share-based compensation recorded in the Company’s consolidated statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures. The Company’s estimated forfeiture rates may differ from its actual forfeitures which would affect the amount of expense recognized during the period.
	The Company values equity awards with a market condition using a Monte Carlo simulation model.
	The Company accounts for stock option grants to non-employees in accordance with provisions which require that the fair value of these instruments be recognized as an expense over the period in which the related services are rendered.
	Share-based compensation expense of awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met. Determining the likelihood and timing of achieving performance conditions is a subjective judgment made by management which may affect the amount and timing of expense related to these share-based awards. Share-based compensation is adjusted to reflect the value of options which ultimately vest as such amounts become known in future periods.
	Valuation of Stock Option Awards
	The assumptions used to compute the share-based compensation costs for the stock options granted during the years ended December 31, 2013, 2012 and 2011 are as follows:
		Year Ended December 31,
		2013		2012			2011
	Risk-free interest rate	1.1-1.8%		0.9-1.2%			1.2-2.5%
	Expected dividend yield	—		—			—
	Weighted average expected life (years)	5.3-5.5		5.3-5.8			5.8-5.9
	Volatility	75-76%		75-78%			56-57%
	Compensation Costs
	The compensation cost that has been included in the Company’s consolidated statement of operations for all stock-based compensation arrangements is detailed as follows (in thousands, except per share amounts):
		Year Ended December 31,
		2013			2012			2011
	Cost of revenues	$	228		$	137		$	180
	Research and development	719			261			289
	Sales and marketing	459			1,695			693
	General and administrative	2,672			1,447			1,263
	Total	$	4,078		$	3,540		$	2,425
	The amounts above include stock-based compensation expense of $1.5 million, $1.3 million and $0 million during the years ended December 31, 2013, 2012 and 2011, respectively, related to the vesting of stock options and awards granted to non-employees under consulting agreements.
Income Taxes	'
	he amounts above include stock-based compensation expense of $1.5 million, $1.3 million and $0 million during the years ended December 31, 2013, 2012 and 2011, respectively, related to the vesting of stock options and awards granted to non-employees under consulting agreements.
	Income Taxes
	The Company accounts for income taxes in accordance with provisions which set forth an asset and liability approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In making such determination, a review of all available positive and negative evidence must be considered, including scheduled reversal of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.
	The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision.
Net Loss per Share	'
	Net Loss per Share
	Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the FASB issued guidance that requires a company to disaggregate the total change of each component of other comprehensive income either on the face of the income statement or as a separate disclosure in the notes. The new guidance became effective for our interim period ended March 31, 2013. The Company adopted this guidance and the adoption did not have any impact on its financial position, results of operations or cash flows.
	In March 2013, the FASB issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments are effective for the Company beginning January 1, 2014. The Company does not anticipate any impact on its financial statements upon adoption.
	In July 2013, the FASB issued guidance that requires an unrecognized tax benefit, or a portion of an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless an exception applies. The Company early adopted this guidance for the period ending December 31, 2013, which is reflected in the Company's consolidated financial statements as of and for the period ended December 31, 2013. There was no material impact on the Company's financial statements upon adoption.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Assumptions Used to Compute Share-Based Compensation Costs for Stock Options Granted	'
	The assumptions used to compute the share-based compensation costs for the stock options granted during the years ended December 31, 2013, 2012 and 2011 are as follows:
		Year Ended December 31,
		2013			2012			2011
	Risk-free interest rate	1.1-1.8%			0.9-1.2%			1.2-2.5%
	Expected dividend yield	—			—			—
	Weighted average expected life (years)	5.3-5.5			5.3-5.8			5.8-5.9
	Volatility	75-76%			75-78%			56-57%
Summary of Compensation Cost for Stock-Based Compensation Arrangements	'
	The compensation cost that has been included in the Company’s consolidated statement of operations for all stock-based compensation arrangements is detailed as follows (in thousands, except per share amounts):
		Year Ended December 31,
		2013				2012			2011
	Cost of revenues	$	228			$	137		$	180
	Research and development	719				261			289
	Sales and marketing	459				1,695			693
	General and administrative	2,672				1,447			1,263
	Total	$	4,078			$	3,540		$	2,425
Weighted Average Number of Common Shares Outstanding	'
	For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive. (In thousands, except per share data):
		Year Ended December 31,
		2013				2012			2011
	Numerator:
	Net loss	$	(82,227	)		$	(15,459	)	$	(22,181	)
	Denominator:
	Weighted average common shares outstanding	97,111				90,870			89,165
	Weighted average unvested common shares subject to repurchase	(876		)		(652		)	(368		)
	Weighted average common shares outstanding—basic	96,235				90,218			88,797
	Effect of dilutive securities:
	Options, warrants and restricted share awards	—				—			—
	Weighted average common shares outstanding—diluted	96,235				90,218			88,797
	Net loss per common share:
	Basic and diluted net loss per share	$	(0.85	)		$	(0.17	)	$	(0.25	)
Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share	'
	The weighted-average anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
		Year Ended December 31,
		2013			2012			2011
	Options to purchase common stock	4,597			4,621			4,323
	Warrants to purchase common stock	594			594			94
	Unvested restricted stock awards	807			877			368
		5,998			6,092			4,785

Acquisitions_and_Investment_Ta

Acquisitions and Investment (Tables) (Phygen, LLC [Member])	12 Months Ended
	Dec. 31, 2013
Phygen, LLC [Member]	'
Business Acquisition [Line Items]	'
Purchase Price Consideration Based on Common Stock and Cash Consideration	'
	Based on the closing price of Alphatec’s common stock of $1.69 on November 6, 2012, cash consideration and contingent liabilities, the total purchase price was as follows (in thousands):
	Fair value of Alphatec common stock issued upon closing	$	8,856
	Cash consideration paid and payable	5,900
	Contingent consideration	3,724
	Total purchase price	$	18,480
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes the allocation of the purchase price for Phygen and the estimated useful lives for the acquired intangible assets (in thousands):
		Useful lives		Estimated
		(in years)		Fair Value
	Net tangible assets assumed			$	1,086
	Acquired intangibles:
	Developed technology	3		176
	Trademarks	3		59
	Covenant not-to-compete	3		389
	Customer-related intangible	12		5,843
	Distribution network	12		2,413
	Goodwill			8,514
	Total purchase price allocation			$	18,480

Balance_Sheet_Details_Tables

Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2013
Balance Sheet Related Disclosures [Abstract]	'
Accounts Receivable	'
	Accounts receivable consist of the following (in thousands):
		December 31,
		2013				2012
	Accounts receivable	$	42,443			$	42,086
	Allowance for doubtful accounts	(1,048		)		(1,074		)
	Accounts receivables, net	$	41,395			$	41,012
Inventories	'
	Inventories consist of the following (in thousands):
		31-Dec-13										31-Dec-12
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	4,375			$	—			$	4,375	$	5,863	$	—		$	5,863
	Work-in-process	531				—				531		1,350		—			1,350
	Finished goods	60,979				(23,946		)		37,033		59,864		(17,222		)	42,642
	Inventories	$	65,885			$	(23,946	)		$	41,939	$	67,077	$	(17,222	)	$	49,855
Property and Equipment	'
	Property and equipment consist of the following (in thousands):
		Useful lives		December 31,
		(in years)		2013				2012
	Surgical instruments	4		$	62,636			$	56,712
	Machinery and equipment	7		14,692				13,996
	Computer equipment	3		3,357				3,269
	Office furniture and equipment	5		3,703				3,528
	Leasehold improvements	various		4,161				4,092
	Building	39		52				64
	Land	n/a		10				13
	Construction in progress	n/a		1,228				1,045
				89,839				82,719
	Less accumulated depreciation and amortization			(61,809		)		(52,316		)
	Property and equipment, net			$	28,030			$	30,403
Intangible Assets	'
	Intangibles assets consist of the following (in thousands):
		Useful lives		December 31,
		(in years)		2013				2012
	Developed product technology	8-Mar		$	23,633			$	23,253
	Distribution rights	3		2,343				4,281
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		17,686				17,423
	Core technology	10		5,137				4,940
	Trademarks and trade names	9-Mar		3,920				3,796
	Customer-related	15-Dec		22,161				19,221
	Distribution network	12-Oct		4,027				3,906
	Physician education programs	10		3,160				3,039
	Supply agreement	10		225				225
				83,296				81,088
	Less accumulated amortization			(44,232		)		(34,232		)
	Intangible assets, net			$	39,064			$	46,856
Future Expected Amortization Expense Related to Intangible Assets	'
	The future expected amortization expense related to intangible assets as of December 31, 2013 is as follows (in thousands):
	Year Ending December 31,
	2014	$	6,751
	2015	6,102
	2016	5,608
	2017	4,986
	2018	3,279
	Thereafter	12,338
	Total	$	39,064
Accrued Expenses	'
	Accrued expenses consist of the following (in thousands):
		December 31,
		2013				2012
	Legal	$	2,139			$	939
	Accounting	928				847
	Phygen purchase price	—				3,936
	Severance	297				749
	Restructuring	9,170				—
	Sales milestones	1,828				2,423
	Accrued taxes	1,120				1,605
	Deferred rent	1,163				1,483
	Royalties	2,347				1,911
	Commissions	6,180				5,371
	Payroll and related	9,369				7,027
	Litigation settlements	22,600				4,102
	Other	5,855				8,097
	Total accrued expenses	$	62,996			$	38,490
Schedule of Changes in Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill from December 31, 2012 through December 31, 2013 were as follows (in thousands):
		December 31,
		2013				2012
	Balance at December 31, 2012 and 2011	$	180,838			$	168,609
	Change in Phygen goodwill	(1,610		)		10,124
	Effect of foreign exchange rate on goodwill	3,776				2,105
	Balance at December 31,	$	183,004			$	180,838

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-term debt consists of the following (in thousands):
		December 31,
		2013			2012
	Credit Facility with MidCap	$	52,081		$	38,634
	Capital leases (See Note 7)	1,336			1,770
	Note payable related to software license purchases	58			59
	Financing agreements for premiums on insurance policies	1,427			1,204
	Total debt	54,902			41,667
	Less: current portion	(4,924		)	(1,700		)
	Total long-term debt	$	49,978		$	39,967
Principal Payments on Debt	'
	Principal payments on debt are as follows as of December 31, 2013 (in thousands):
	Year Ending December 31,
	2014	$	4,485
	2015	3,000
	2016	46,081
	2017	—
	2018	—
	Thereafter	—
	Total	53,566
	Add: capital lease principal payments	1,336
	Total	54,902
	Less: current portion of long-term debt	(4,924		)
	Long-term debt, net of current portion	$	49,978

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Annual Lease Payments	'
	Future minimum annual lease payments under the Company’s operating and capital leases are as follows (in thousands):
	Year ending December 31,	Operating		Capital
	2014	$	3,346	$	527
	2015	2,725		467
	2016	1,363		425
	2017	216		82
	2018	15		—
	Thereafter	—		—
		$	7,665	1,501
	Less: amount representing interest			(165		)
	Present value of minimum lease payments			1,336
	Current portion of capital leases			(439		)
	Capital leases, less current portion			$	897

Stock_Benefit_Plans_and_StockB1

Stock Benefit Plans and Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Stock Option Activity	'
	A summary of the Company’s stock option activity under the 2005 Plan and related information is as follows (in thousands, except as indicated and per share data):
		Shares		Weighted		Weighted	Aggregate
				average		average	intrinsic
				exercise		remaining	value
				price		contractual
						term
						(in years)
	Outstanding at December 31, 2012	4,920		$	2.51	8.03	$	64
	Granted	4,541		$	1.9	—	—
	Exercised	(6	)	$	1.54	—	—
	Forfeited	(1,645	)	$	2.12	—	—
	Outstanding at December 31, 2013	7,810		$	2.23	7.59	$	753
	Options vested and exercisable at December 31, 2013	2,640		$	2.79	6.1	$	125
	Options vested and expected to vest at December 31, 2013	7,218		$	2.26	7.51	$	679
Summary of Information about Restricted Stock Awards Activity	'
	The following table summarizes information about the restricted stock awards activity (in thousands, except as indicated and per share data):
		Shares		Weighted		Weighted
				average		average
				grant		remaining
				date fair		recognition
				value		period
						(in years)
	Unvested at December 31, 2012	877		$	1.81	1.49
	Awarded	375		$	1.97
	Vested	(375	)	$	1.84
	Forfeited	(70	)	$	1.65
	Unvested at December 31, 2013	807		$	1.88	2.3
Summary of Common Stock Reserved for Future Issuance	'
	Common stock reserved for future issuance consists of the following (in thousands):
		31-Dec-13
	Stock options outstanding	7,810
	Awards outstanding	807
	Warrants outstanding	594
	Authorized for future grant under 2005 Plan	3,166
		12,377

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components of Pretax Loss from Operations	'
	The components of the pretax loss from operations for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands):
		Year Ended December 31,
		2013				2012				2011
	U.S. Domestic	$	(9,264	)		$	(3,310	)		$	(14,400	)
	Foreign	(69,784		)		(13,308		)		(12,288		)
	Pretax loss from operations	$	(79,048	)		$	(16,618	)		$	(26,688	)
Components of (Benefit) Provision for Income Taxes	'
	The components of the (benefit) provision for income taxes are presented in the following table (in thousands):
		Year Ended December 31,
		2013				2012				2011
	Current:
	Federal	$	(21	)		$	107			$	4
	State	186				24				222
	Foreign	2,525				2,083				(388		)
	Total current provision (benefit)	2,690				2,214				(162		)
	Deferred:
	Federal	229				137				163
	State	15				29				8
	Foreign	245				(3,539		)		(4,516		)
	Total deferred provision (benefit)	489				(3,373		)		(4,345		)
	Total provision (benefit)	$	3,179			$	(1,159	)		$	(4,507	)
Schedule of Effective Income Tax Rate Reconciliation	'
	The (benefit) provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to pretax income as a result of the following differences:
		December 31,
		2013			2012			2011
	Federal statutory rate	(35.0	)%		(35.0	)%		(35.0	)%
	Adjustments for tax effects of:
	State taxes, net	(0.1	)%		(0.0	)%		(0.7	)%
	Stock-based compensation	0.5	%		(0.5	)%		1.8	%
	Foreign taxes	1.1	%		(0.1	)%		3.6	%
	Tax credits	(0.4	)%		(0.7	)%		(1.2	)%
	Deemed foreign dividend	—	%		0.2	%		10.3	%
	Intercompany debt forgiveness and other permanent adjustments	9.5	%		5	%		0.8	%
	Tax rate adjustment	0.2	%		0.7	%		(0.5	)%
	Uncertain tax positions	2.7	%		14.9	%		(1.5	)%
	Other	(0.4	)%		3.3	%		(3.1	)%
	Valuation allowance	25.9	%		5.2	%		8.7	%
		4	%		(7.0	)%		(16.8	)%
Significant Components of Company's Deferred Tax Assets and Liabilities	'
	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows (in thousands):
		December 31,
		2013				2012
	Deferred tax assets:
	Allowances and reserves	$	816			$	1,088
	Accrued expenses	3,685				648
	Inventory reserves	7,549				7,839
	Net operating loss carryforwards	26,497				28,786
	Property and equipment	1,171				—
	Stock-based compensation	2,769				1,866
	Legal settlement	17,998				4,156
	Income tax credit carryforwards	1,800				1,276
		62,285				45,659
	Valuation allowance	(56,690		)		(36,031		)
	Total deferred tax assets, net of valuation allowance	5,595				9,628
	Deferred tax liabilities:
	Property and equipment	—				926
	Intangible assets	4,806				6,910
	Goodwill	1,256				1,011
	Total deferred tax liabilities	6,062				8,847
	Net deferred tax assets (liabilities)	$	(467	)		$	781
Summary of Changes to Unrecognized Tax Benefits	'
	The following table summarizes the changes to unrecognized tax benefits for the years ended December 31, 2013, 2012 and 2011 (in thousands):
	Balance at December 31, 2010	$	4,421
	Additions based on tax positions related to the prior year	73
	Additions based on tax positions related to the current year	399
	Reductions as a result of positions taken	(59		)
	Reductions as a result of lapse of applicable statute of limitations	(649		)
	Additions as a result of foreign exchange rates and other	12
	Balance at December 31, 2011	$	4,197
	Additions based on tax positions related to the prior year	987
	Additions based on tax positions related to the current year	743
	Reductions as a result of lapse of applicable statute of limitations	(58		)
	Additions as a result of foreign exchange rates and other	28
	Balance at December 31, 2012	$	5,897
	Additions based on tax positions related to the prior year	221
	Additions based on tax positions related to the current year	1,664
	Reductions as a result of lapse of applicable statute of limitations	(20		)
	Additions as a result of foreign exchange rates and other	73
	Balance at December 31, 2013	$	7,835

Segment_and_Geographical_Infor1

Segment and Geographical Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Revenues Attributed to Geographic Location of Customer	'
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Year Ended December 31,
		2013		2012		2011
	United States	$	134,951	$	130,476	$	133,824
	International	69,773		65,802		63,887
	Total consolidated revenues	$	204,724	$	196,278	$	197,711
Schedule of Long Lived Assets by Geographical Areas	'
	Total assets by region were as follows (in thousands):
		December 31,
		2013		2012
	United States	$	196,383	$	213,912
	International	169,247		168,215
	Total consolidated assets	$	365,630	$	382,127

Restructuring_Activities_Table

Restructuring Activities (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring Reserve Movement	'
	Below is a table of the movement (in thousands):
		Expensed		Paid and			Accrued		Total		Remaining
		31-Dec-13		Other			31-Dec-13		Costs		Costs
	Social plan	$	8,893	$	(84	)	$	8,809	$	9,705	$	535
	French non-social plan costs	210		(210		)	—		2,162		2,162
	US booked social cost	361		—			361		—		—
	US costs other	201		(201		)	—		—		—
	Total	$	9,665	$	(495	)	$	9,170	$	11,867	$	2,697

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Quarterly Financial Data	'
	The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for fiscal 2013 and 2012 are as follows (in thousands, except per share data):
		Year ended December 31, 2013
		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
	Selected quarterly financial data:
	Revenue	$	50,443		$	51,020		$	50,196		$	53,065
	Gross profit	32,742			32,093			24,232			35,255
	Total operating expenses	34,100			34,992			37,406			91,257
	Net loss	(2,649		)	(4,661		)	(14,510		)	(60,407		)
	Basic and diluted net loss per common share (1)	(0.03		)	(0.05		)	(0.15		)	(0.62		)
		Year ended December 31, 2012
		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
	Selected quarterly financial data:
	Revenue	$	48,461		$	48,235		$	46,839		$	52,743
	Gross profit	31,819			30,196			29,633			32,120
	Total operating expenses	31,944			33,947			31,606			36,108
	Net loss	(1,261		)	(6,374		)	(2,469		)	(5,355		)
	Basic and diluted net loss per common share (1)	(0.01		)	(0.07		)	(0.03		)	(0.06		)
	-1	Basic and diluted net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal the total for the year.

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
		Market
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'	'
Number of market for products	'	50	'	'	'
Cash and cash equivalents	'	$21,345,000	$22,241,000	$20,666,000	$23,168,000
Other working capital	$12,700,000	'	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
		Product
Significant Accounting Policies [Line Items]	'	'	'	'
Percentage of consolidated revenues held by customer	'	10.00%	'	'
Deferred revenue	$1,009,000	$1,009,000	$1,361,000	'
Inventory at consigned location	18,400,000	18,400,000	22,000,000	'
Number of products no longer actively market	'	2	'	'
Impairment charges	'	1,300,000	'	'
Percentage of weighted average cost of capital discount rate	'	12.00%	'	'
Fair Value Inputs, Long-term Revenue Growth Rate	'	4.00%	'	'
Foreign currency gains	'	-1,700,000	-900,000	500,000
Contingent consideration	3,800,000	'	'	'
Product shipment costs	'	3,100,000	2,900,000	3,600,000
Stock-based compensation expense	'	$1,500,000	$1,300,000	$0
Minimum [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Estimated useful lives of property and equipment	'	'3 years	'	'
Fair Value Inputs, Long-term Revenue Growth Rate	'	4.00%	'	'
Intangible assets, amortization period	'	'1 year	'	'
Maximum [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Estimated useful lives of property and equipment	'	'7 years	'	'
Fair Value Inputs, Long-term Revenue Growth Rate	'	12.00%	'	'
Intangible assets, amortization period	'	'15 years	'	'
Sales [Member] | Customer Concentration Risk [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Concentration risk, number of customers	'	0	0	0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Assumptions Used to Compute Share-Based Compensation Costs for Stock Options Granted (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate, minimum	1.10%	0.90%	1.20%
Risk-free interest rate, maximum	1.80%	1.20%	2.50%
Expected dividend yield	'	'	'
Volatility, minimum	75.00%	75.00%	56.00%
Volatility, maximum	76.00%	78.00%	57.00%
Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Weighted average expected life (years)	'5 years 3 months 18 days	'5 years 3 months 18 days	'5 years 9 months 18 days
Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Weighted average expected life (years)	'5 years 6 months	'5 years 9 months 18 days	'5 years 10 months 24 days

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Compensation Cost for Stock-Based Compensation Arrangements (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense	$4,078	$3,540	$2,425
Cost of revenues [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense	228	137	180
Research and development [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense	719	261	289
Sales and marketing [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense	459	1,695	693
General and administrative [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense	$2,672	$1,447	$1,263

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Weighted Average Number of Common Shares Outstanding (Detail) (USD $)

3 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Numerator:

'

'

'

'

'

'

'

'

'

'

'

Net loss

($60,407)

($14,510)

($4,661)

($2,649)

($5,355)

($2,469)

($6,374)

($1,261)

($82,227)

($15,459)

($22,181)

Denominator:

'

'

'

'

'

'

'

'

'

'

'

Weighted average common shares outstanding

'

'

'

'

'

'

'

'

97,111

90,870

89,165

Weighted average unvested common shares subject to repurchase

'

'

'

'

'

'

'

'

-876

-652

-368

Weighted average common shares outstanding—basic

'

'

'

'

'

'

'

'

96,235

90,218

88,797

Effect of dilutive securities:

'

'

'

'

'

'

'

'

'

'

'

Options, warrants and restricted share awards

'

'

'

'

'

'

'

'

'

'

'

Weighted average common shares outstanding—diluted

'

'

'

'

'

'

'

'

96,235

90,218

88,797

Net loss per common share:

'

'

'

'

'

'

'

'

'

'

'

Basic and diluted net loss per share

($0.62)

[1]

($0.15)

[1]

($0.05)

[1]

($0.03)

[1]

($0.06)

[1]

($0.03)

[1]

($0.07)

[1]

($0.01)

[1]

($0.85)

($0.17)

($0.25)

[1]

Basic and diluted net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal the total for the year.

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share (Detail)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities not included in diluted net loss per share	5,998	6,092	4,785
Options to purchase common stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities not included in diluted net loss per share	4,597	4,621	4,323
Warrants to purchase common stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities not included in diluted net loss per share	594	594	94
Unvested restricted stock awards [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities not included in diluted net loss per share	807	877	368

Acquisitions_and_Investment_Ad

Acquisitions and Investment - Additional Information (Detail) (USD $)	3 Months Ended				1 Months Ended	0 Months Ended	1 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Nov. 06, 2012	Dec. 31, 2011	Jan. 31, 2011	Nov. 06, 2012	Nov. 30, 2013	Nov. 06, 2012	Nov. 06, 2013	Apr. 30, 2013	Dec. 31, 2012
					Cibramed [Member]	Phygen, LLC [Member]	Phygen, LLC [Member]	Phygen, LLC [Member]	Phygen, LLC [Member]	Phygen, LLC [Member]	Phygen, LLC [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Effective acquisition date	'	'	'	'	'	6-Nov-12	'	'	'	'	'
Number of shares issued to acquire business after reducing acquisition fees and expenses	'	'	'	'	'	4,069,087	'	'	'	'	'
Cash paid at closing of Purchase Agreement	'	'	'	'	'	$2,000,000	'	$2,000,000	'	'	'
Unregistered shares of common stock placed in escrow account	'	'	'	'	'	1,170,960	'	1,170,960	'	'	'
Length of time following closing to keep security against potential indemnification obligations	'	'	'	'	'	'12 months	'	'	'	'	'
Number of common stock claimed against escrow shares	'	'	'	'	'	'	328,356	'	'	'	'
Income related to common stock claimed against escrow shares	'	'	'	'	'	'	600,000	'	'	'	'
Cash paid to set-off for indemnification claims	'	'	'	'	'	'	'	'	'	4,000,000	'
Business acquisition, transaction related expenses	'	'	'	'	'	'	'	'	'	'	1,100,000
Closing price of share	'	'	$1.69	'	'	'	'	'	'	'	'
Net tangible assets assumed	'	'	'	'	'	1,086,000	'	1,086,000	'	'	'
Acquired intangible assets	'	'	'	'	'	8,900,000	'	8,900,000	'	'	'
Contingent consideration	3,800,000	'	'	'	'	'	'	'	3,724,000	'	'
Goodwill	183,004,000	180,838,000	'	168,609,000	'	8,514,000	'	8,514,000	'	'	'
Inventory setup reversal period	'	'	'	'	'	'	'	'6 months	'	'	'
Net intangible assets purchased	'	'	'	'	600,000	'	'	'	'	'	'
Estimated life of asset	'	'	'	'	'15 years	'	'	'	'	'	'
Total purchase price	'	'	'	'	$600,000	'	'	'	$18,480,000	'	'
Percentage of total purchase price to be paid in the first installment	'	'	'	'	60.00%	'	'	'	'	'	'
Percentage of total purchase price to be paid in the second installment	'	'	'	'	20.00%	'	'	'	'	'	'
Length of time of payment due in the second installment	'	'	'	'	'90 days	'	'	'	'	'	'
Percentage of total purchase price to be paid in the third installment	'	'	'	'	20.00%	'	'	'	'	'	'
Length of time of payment due in the third installment	'	'	'	'	'180 days	'	'	'	'	'	'

Acquisitions_and_Investment_Pu

Acquisitions and Investment - Purchase Price Consideration Based on Common Stock and Cash Consideration (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Nov. 06, 2013
		Phygen, LLC [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'
Fair value of Alphatec common stock issued upon closing	'	$8,856
Cash consideration paid and payable	'	5,900
Contingent consideration	3,800	3,724
Total purchase price	'	$18,480

Acquisitions_and_Investment_Al

Acquisitions and Investment - Allocation of Purchase Price and Estimated Useful Life of Assets Acquired (Detail) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 06, 2012

Dec. 31, 2013

Nov. 06, 2012

Dec. 31, 2013

Nov. 06, 2012

Dec. 31, 2013

Nov. 06, 2012

Dec. 31, 2013

Nov. 06, 2012

Dec. 31, 2013

Nov. 06, 2012

In Thousands, unless otherwise specified

Phygen, LLC [Member]

Developed technology [Member]

Developed technology [Member]

Trademarks [Member]

Trademarks [Member]

Covenant not-to-compete [Member]

Covenant not-to-compete [Member]

Customer-related intangible [Member]

Customer-related intangible [Member]

Distribution network [Member]

Distribution network [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Phygen, LLC [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired intangibles, Useful lives (in years)

'

'

'

'

'3 years

'

'3 years

'

'3 years

'

'12 years

'

'12 years

'

Net tangible assets assumed, Estimated Fair Value

'

'

'

$1,086

'

'

'

'

'

'

'

'

'

'

Acquired intangibles, Estimated Fair Value

'

'

'

8,900

'

176

'

59

'

389

'

5,843

'

2,413

Goodwill

183,004

180,838

168,609

8,514

'

'

'

'

'

'

'

'

'

'

Total purchase price allocation

'

'

'

$18,480

'

'

'

'

'

'

'

'

'

'

Balance_Sheet_Details_Accounts

Balance Sheet Details - Accounts Receivable (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Accounts receivable	$42,443	$42,086
Allowance for doubtful accounts	-1,048	-1,074
Accounts receivables, net	$41,395	$41,012

Balance_Sheet_Details_Inventor

Balance Sheet Details - Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Raw materials, Gross	$4,375	$5,863
Work-in-process, Gross	531	1,350
Finished goods, Gross	60,979	59,864
Inventory, Gross, Total	65,885	67,077
Finished goods, Reserve for excess and obsolete	-23,946	-17,222
Inventories, net, Reserve for excess and obsolete	-23,946	-17,222
Raw materials Net	4,375	5,863
Work-in-process, Net	531	1,350
Finished goods, Net	37,033	42,642
Inventories, Net	$41,939	$49,855

Balance_Sheet_Details_Property

Balance Sheet Details - Property and Equipment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$89,839	$82,719
Less accumulated depreciation and amortization	-61,809	-52,316
Property and equipment, net	28,030	30,403
Surgical instruments [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'4 years	'
Property, Plant and Equipment, Gross	62,636	56,712
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'7 years	'
Property, Plant and Equipment, Gross	14,692	13,996
Computer equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'3 years	'
Property, Plant and Equipment, Gross	3,357	3,269
Office furniture and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'5 years	'
Property, Plant and Equipment, Gross	3,703	3,528
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Various useful life of property and equipment	'various	'
Property, Plant and Equipment, Gross	4,161	4,092
Building [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'39 years	'
Property, Plant and Equipment, Gross	52	64
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	10	13
Construction in progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$1,228	$1,045

Balance_Sheet_Details_Addition

Balance Sheet Details - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Product
Property, Plant and Equipment [Line Items]	'	'	'
Total depreciation expense	$14.60	$14.20	$14.80
Total amortization expense	11.6	9.6	5.1
Number of products no longer actively market	2	'	'
Impairment charges	1.3	'	'
Machinery and equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Capital Leased Assets, Gross	1.8	'	'
Construction in progress [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Capital Leased Assets, Gross	'	$0.60	'

Balance_Sheet_Details_Intangib

Balance Sheet Details - Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Developed product technology	$23,633	$23,253
Intellectual property	1,004	1,004
License agreements	17,686	17,423
Core technology	5,137	4,940
Trademarks and trade names	3,920	3,796
Customer-related	22,161	19,221
Distribution network	4,027	3,906
Physician education programs	3,160	3,039
Supply agreement	225	225
Intangible assets, Gross	83,296	81,088
Less accumulated amortization	-44,232	-34,232
Intangible assets, net	39,064	46,856
Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'1 year	'
Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'15 years	'
Developed product technology [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'3 years	'
Developed product technology [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'8 years	'
Distribution rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'3 years	'
Distribution rights	$2,343	$4,281
Intellectual property [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'5 years	'
License agreements [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'1 year	'
License agreements [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'7 years	'
Core technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'10 years	'
Trademarks and trade names [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'3 years	'
Trademarks and trade names [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'9 years	'
Customer-related [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'12 years	'
Customer-related [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'15 years	'
Distribution network [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'10 years	'
Distribution network [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'12 years	'
Physician education programs [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'10 years	'
Supply agreement [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives	'10 years	'

Balance_Sheet_Details_Future_E

Balance Sheet Details - Future Expected Amortization Expense Related to Intangible Assets (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'
2014	$6,751
2015	6,102
2016	5,608
2017	4,986
2018	3,279
Thereafter	12,338
Total future expected amortization expense	$39,064

Balance_Sheet_Details_Accrued_

Balance Sheet Details - Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Legal	$2,139	$939
Accrued Professional Fees, Current	928	847
Phygen purchase price	0	3,936
Severance	297	749
Restructuring	9,170	0
Sales milestones	1,828	2,423
Accrued taxes	1,120	1,605
Deferred rent	1,163	1,483
Royalties	2,347	1,911
Commissions	6,180	5,371
Payroll and related	9,369	7,027
Litigation settlements	22,600	4,102
Other	5,855	8,097
Total accrued expenses	$62,996	$38,490

Balance_Sheet_Details_Schedule

Balance Sheet Details - Schedule of Changes in Carrying Amount of Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Roll Forward]	'	'
Balance at December 31, 2012 and 2011	$180,838	$168,609
Change in Phygen goodwill	-1,610	10,124
Effect of foreign exchange rate on goodwill	3,776	2,105
Balance at December 31,	$183,004	$180,838

License_and_Consulting_Agreeme1

License and Consulting Agreements - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2012

Jun. 30, 2012

Jun. 30, 2009

Dec. 15, 2010

Dec. 31, 2013

Nov. 30, 2010

Dec. 31, 2007

Dec. 31, 2010

Dec. 31, 2013

Jan. 31, 2010

Sep. 30, 2013

Sep. 30, 2010

Sep. 30, 2010

Mar. 31, 2010

Sep. 30, 2010

Feb. 28, 2009

Sep. 30, 2010

Nov. 30, 2012

Sep. 30, 2010

Oct. 31, 2013

Supply agreement [Member]

Supply agreement [Member]

License Agreements [Member]

OsseoScrew License Agreement [Member]

OsseoScrew License Agreement [Member]

OsseoScrew License Agreement [Member]

OsseoScrew License Agreement [Member]

OsseoScrew License Agreement [Member]

OsseoScrew License Agreement [Member]

Distribution Agreement with Parcell Spine, LLC [Member]

Distribution Agreement with Parcell Spine, LLC [Member]

Distribution Agreement with Parcell Spine, LLC [Member]

Distribution Agreement with Parcell Spine, LLC [Member]

Distribution Agreement with Parcell Spine, LLC [Member]

Distribution Agreement with Parcell Spine, LLC [Member]

License Agreement with Helix Point, LLC [Member]

License Agreement with Helix Point, LLC [Member]

License Agreement with R Tree Innovations LLC [Member]

License Agreement with R Tree Innovations LLC [Member]

License Agreement with R Tree Innovations LLC [Member]

Research and Development Arrangement [Member]

Initial cash payment [Member]

Development Milestone Payments [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Up-front payment paid

'

'

'

'

$1,000,000

$1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement term

'

'

'

'

'7 years

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum purchase requirements

'

'

'

'

5,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payments

'

'

'

'

'

'

'

'

'

1,500,000

3,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional milestone payments

'

'

'

'

'

'

'

'

300,000

'

2,500,000

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

Reversal of accrual for milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

Intangible assets

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

200,000

'

1,300,000

500,000

Cash payment

300,000

'

'

'

'

'

'

'

'

'

'

1,500,000

'

500,000

'

500,000

1,000,000

'

'

200,000

'

300,000

800,000

'

Issuance of common stock

200,000

'

'

'

'

'

260,000

'

'

1,000,000

'

1,000,000

'

1,000,000

'

1,000,000

1,000,000

'

'

400,000

'

200,000

500,000

'

Intangible assets, amortization period

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'7 years

'

'

'

'

'7 years

'7 years

'

'

Number of shares of Common stock

'

'

'

'

'

'

'

452,488

'

'

'

'

'

'

'

476,190

'

'

465,116

'

'

367,044

'

'

In process research and development expense ("IPR&D")

'

14,190,000

14,886,000

16,888,000

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

500,000

'

'

'

'

'

'

Addition in intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

Amortization of acquired intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

'

'

'

'

'

'

'

'

Provision for excess and obsolete inventory

'

$11,652,000

$6,658,000

$4,564,000

'

'

'

'

'

'

'

'

'

'

$2,600,000

'

'

'

'

'

'

'

'

'

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Feb. 28, 2013

Oct. 29, 2010

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 07, 2012

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Aug. 30, 2013

Dec. 31, 2013

Jul. 30, 2013

Dec. 31, 2013

Aug. 30, 2013

Aug. 30, 2013

Dec. 31, 2013

Aug. 30, 2013

Dec. 31, 2013

Aug. 30, 2013

Minimum [Member]

Maximum [Member]

Silicon Valley Bank [Member]

Working capital line of credit [Member]

Term loan [Member]

Credit Facility third amendment [Member]

Credit Facility third amendment [Member]

Credit Facility third amendment [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Installment

Term Loan Drawn On Closing [Member]

Term Loan Drawn On Closing [Member]

Term Loan. Delayed Draw [Member]

Credit Facility [Member]

Credit Facility [Member]

Term loan [Member]

Term loan [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

$50,000,000

'

'

'

'

'

'

'

'

$73,000,000

'

$50,000,000

$28,000,000

$28,000,000

$5,000,000

'

$40,000,000

'

$33,000,000

Length of period of term loan delayed draw

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

Working capital line of credit, repaid

'

'

'

168,855,000

99,853,000

17,346,000

'

'

'

8,100,000

168,900,000

'

'

'

'

28,000,000

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Interest Rate Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'LIBOR plus 6.0%

'

'("LIBOR") plus 8.0%

'

Basis spread on variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

'

8.00%

'

Line of Credit Facility, Floor on Interest Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.50%

'

Interest rate of revolving line of credit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.20%

'

9.50%

'

Term loan payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

Debt issuance costs

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

Unamortized debt issuance and debt discount costs

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

Borrowing capacity

'

'

'

'

'

'

40,000,000

'

'

'

'

'

22,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility used to pay off its existing term loan

'

'

'

34,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Existing line of credit

'

'

'

'

'

'

'

'

'

17,600,000

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Early termination and other fees

'

'

'

'

2,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt costs

'

'

2,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Up-front commitment fee

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt default accrued interest rate

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit, total amount drawn

'

'

'

'

'

'

'

'

'

'

154,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit, balance

'

'

'

52,081,000

38,634,000

'

'

'

'

'

24,800,000

27,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-cash interest expense

'

'

'

200,000

900,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense

'

'

'

3,600,000

2,600,000

2,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit, amendment date

'

29-Oct-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revolving line of credit interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.50%

'

'

'

'

'

'

'

'

'

'

Line of credit facility amendment fee

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Working capital line of credit, prime rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.50%

'

'

'

'

'

'

'

'

'

'

Equal quarterly installments

'

'

'

'

'

'

'

'

'

'

'

'

'

16

'

'

'

'

'

'

'

'

'

'

'

Capital leases interest percentage

'

'

'

'

'

'

'

6.60%

9.60%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt_Long_Term_Debt_Detail

Debt - Long -Term Debt (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Credit Facility with MidCap	$52,081	$38,634
Capital leases (See Note 7)	1,336	1,770
Note payable related to software license purchases	58	59
Financing agreements for premiums on insurance policies	1,427	1,204
Total debt	54,902	41,667
Less: current portion	-4,924	-1,700
Total long-term debt	$49,978	$39,967

Debt_Principal_Payments_on_Deb

Debt - Principal Payments on Debt (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
2014	$4,485	'
2015	3,000	'
2016	46,081	'
2017	0	'
2018	0	'
Thereafter	0	'
Total	53,566	'
Add: capital lease principal payments	1,336	'
Total debt	54,902	41,667
Less: current portion of long-term debt	-4,924	-1,700
Long-term debt, net of current portion	$49,978	$39,967

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2004

Jul. 31, 2005

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

31-May-08

Dec. 31, 2007

Dec. 31, 2006

31-May-08

Jan. 08, 2014

Feb. 10, 2014

Mar. 15, 2014

Mar. 15, 2014

Mar. 15, 2014

Mar. 15, 2014

Mar. 15, 2014

Scient'x [Member]

Surgiview [Member]

Lease agreement [Member]

Lease agreement [Member]

Lease agreement [Member]

Sublease [Member]

Sublease [Member]

Sublease [Member]

Healthpoint Capital [Member]

Eurosurgical [Member]

Eurosurgical [Member]

Minimum [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

CreditFacility

First year [Member]

Final year [Member]

First year [Member]

Final year [Member]

Scient'x [Member]

Healthpoint Capital [Member]

Healthpoint Capital [Member]

Eurosurgical [Member]

Subsequent Event [Member]

Subsequent Event [Member]

By March 31, 2014 [Member]

By April 11, 2014 [Member]

Beginning Fourth Quarter of 2014 [Member]

Scient'x [Member]

Scient'x [Member]

Healthpoint Capital [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rent payable final year of Sublease

'

'

'

'

'

'

'

'

'

$80,500

$93,500

'

'

'

'

'

'

'

'

'

'

'

Fixed annual rate

'

'

'

'

'

3.00%

'

'

2.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

Security deposit

'

'

'

'

'

293,200

'

'

93,500

'

'

'

'

'

'

'

'

'

'

'

'

'

Rent payable for leases

'

'

'

'

'

'

73,500

93,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease rent abated

'

'

'

'

'

38,480

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Letter of credit issued for security deposit

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tenant improvement allowance

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rent expenses

3,800,000

3,700,000

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual claim settlement liability

'

'

'

'

'

'

'

'

'

'

'

'

30,000,000

9,000,000

'

'

'

49,000,000

'

1,750,000

15,750,000

31,500,000

Percentage of interests acquired

'

'

'

33.10%

73.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss contingency, damages sought, value

'

'

'

'

'

'

'

'

'

'

'

39,000,000

'

'

70,000,000

'

47,900,000

'

'

'

'

'

Length of period after closing a financing for the Company to make additional settlement payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'25 days

'

Litigation settlement, quarterly installments, amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

Litigation settlement, contribution by entity involved

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

Litigation settlement interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

Litigation settlement interest, quarterly installments, amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

Attorneys' fees paid by insurance carriers

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,250,000

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Annual Lease Payments (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
Operating leases 2014	$3,346
Operating leases 2015	2,725
Operating leases 2016	1,363
Operating leases 2017	216
Operating leases 2018	15
Operating leases Thereafter	0
Operating leases, Total	7,665
Capital leases 2014	527
Capital leases 2015	467
Capital leases 2016	425
Capital leases 2017	82
Capital leases 2018	0
Capital leases Thereafter	0
Capital leases, Total	1,501
Less: amount representing interest	-165
Present value of minimum lease payments	1,336
Current portion of capital leases	-439
Capital leases, less current portion	$897

Redeemable_Preferred_Stock_and1

Redeemable Preferred Stock and Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	8-May-12	Dec. 31, 2013	Dec. 31, 2012
			Eclipse Advisors, LLC [Member]	Redeemable preferred stock [Member]	Redeemable preferred stock [Member]
			Tranche
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'
Redeemable preferred stock carrying value	$23,603,000	$23,603,000	'	$23,600,000	'
Redeemable preferred stock authorized	20,000,000	20,000,000	'	20,000,000	'
Redemption value per share will be reported as dividend	$9	'	'	'	'
Redeemable preferred stock, price per share	'	'	'	$7.11	$7.11
Redeemable preferred stock redemption, price per share	'	'	'	$9	'
Commitment to purchase shares of common stock, amount, maximum	'	'	25,000,000	'	'
Term of investment agreement	'	'	'24 months	'	'
Number of tranches to purchase common stock	'	'	2	'	'
Period for purchase common stock in two tranches	'	'	'31 days	'	'
Percentage of common stock to be purchase on 16th day after date of put notice	'	'	50.00%	'	'
Percentage of common stock to be purchase on 31st day after date of put notice	'	'	50.00%	'	'
Percentage of volume weighted average price of common stock used to determine per share price	'	'	90.00%	'	'
Number of trading days taken for estimating shares for issuance	'	'	'15 days	'	'
Maximum percentage of committed shares of common stock after sending cancellation notice	'	'	50.00%	'	'
Issuance of common stock	'	'	231,045	'	'
Commitment fee	'	'	$500,000	'	'
Number of Trading Days Proceeding Investment Agreement Effective Date to Determine Commitment Fee	'	'	'5 days	'	'

Stock_Benefit_Plans_and_StockB2

Stock Benefit Plans and Stock-Based Compensation - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Nov. 19, 2012

Dec. 19, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2012

31-May-13

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 19, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

31-May-13

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 31, 2013

Dec. 31, 2013

Quarter

Media Advertising Agreement [Member]

Media Advertising Agreement [Member]

Media Advertising Agreement [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Warrants [Member]

Warrants [Member]

Stock options [Member]

Stock options [Member]

Stock options [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Registered shares [Member]

Registered shares [Member]

Unregistered shares [Member]

2005 Plan [Member]

2005 Plan [Member]

2005 Plan [Member]

2005 Plan [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Media Advertising Agreement [Member]

Media Advertising Agreement [Member]

Media Advertising Agreement [Member]

Maximum [Member]

Minimum [Member]

Incentive stock options [Member]

payment

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for issuance

'

'

12,377,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,200,000

'

'

'

'

'

Options granted expiration term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'5 years

'

'

Stock options voting rights, percentage (more than 10%)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

Share based payment award options, vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

Exercise price of incentive stock options, percent (less than 100%)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

Exercise price of option granted to stock holder, percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

Exercise price of stock options granted to 10 percent stockholder , percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110.00%

'

'

'

'

'

Shares of common stock remained available for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,200,000

'

'

'

'

'

Weighted-average grant-date fair value of stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.09

$1.10

$1.48

'

'

'

'

'

'

'

'

'

'

'

'

Closing stock price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation expense for stock options and awards expected to be recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Straight-line basis over a weighted average period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 8 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total intrinsic value of options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock options exercise price

$2

$2.05

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.85

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options exercise price percentage

115.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exchanged options issued to optionees for a reduced number of options

'

1,109,604

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exchanged option vesting period

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of award vesting on the first anniversary

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of quarterly vesting installments

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average fair value of awards granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.97

$1.57

$2.61

'

'

'

'

'

'

'

'

'

Purchase of common stock shares for issuance of warrants

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

93,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

2.5

'

'

'

'

'

'

'

'

'

'

1.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expiration date

'

'

'March 1, 2015

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting percentage of warrants

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility, finance charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants risk free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.23%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants volatility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expected term

'

'

'

'

'

'

'

'

'

'5 years 6 months

'5 years 9 months 18 days

'5 years 10 months 24 days

'5 years 3 months 18 days

'5 years 3 months 18 days

'5 years 9 months 18 days

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative arrangement term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

Collaborative arrangement, number of periodic payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

Collaborative arrangement, periodic payment aggregate amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

'

Collaborative payments, per share price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.95

'

Number of days leading up to and including date of signing collaboration agreement for per share price used to calculate annual payments to collaborator

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 days

'

Number of months of services provided for number of shares issued used to calculate annual payments to collaborator

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

Consulting fees paid

'

'

'

'

'

'

200,000

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

97,599,000

96,703,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

225,000

500,000

352,000

'

'

'

'

'

128,571

Stock based compensation

'

'

$4,078,000

$3,690,000

$2,425,000

'

'

$700,000

$1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Benefit_Plans_and_StockB3

Stock Benefit Plans and Stock-Based Compensation - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Shares Outstanding, Beginning balance	4,920	'
Shares, Granted	4,541	'
Shares, Exercised	-6	'
Shares, Forfeited	-1,645	'
Shares Outstanding, Ending balance	7,810	4,920
Shares, Options vested and exercisable	2,640	'
Shares, Options vested and expected to vest	7,218	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]	'	'
Weighted average exercise price, Outstanding, Beginning balance	$2.51	'
Weighted average exercise price, Granted	$1.90	'
Weighted average exercise price, Exercised	$1.54	'
Weighted average exercise price, Forfeited	$2.12	'
Weighted average exercise price, Outstanding, Ending balance	$2.23	$2.51
Weighted average exercise price, Options vested and exercisable	$2.79	'
Weighted average exercise price, Options vested and expected to vest	$2.26	'
Weighted average remaining contractual term (in years), Outstanding, balance	'7 years 7 months 2 days	'8 years 0 months 11 days
Options vested and exercisable at December 31, 2013, Weighted average remaining contractual term (in years)	'6 years 1 month 6 days	'
Options vested and expected to vest at December 31, 2013, Weighted average remaining contractual term (in years)	'7 years 6 months 4 days	'
Aggregate intrinsic value, Outstanding, Beginning balance	$64	'
Aggregate intrinsic value, Granted	0	'
Aggregate intrinsic value, Exercised	0	'
Aggregate intrinsic value, Forfeited	0	'
Aggregate intrinsic value, Outstanding, Ending balance	753	64
Aggregate intrinsic value, Options vested and exercisable	125	'
Aggregate intrinsic value, Options vested and expected to vest	$679	'

Stock_Benefit_Plans_and_StockB4

Stock Benefit Plans and Stock-Based Compensation - Summary of Information about Restricted Stock Awards Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Common stock reserved for future issuance	12,377	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'	'
Shares, Unvested beginning balance	877	'
Shares, Awarded	375	'
Shares, Vested	-375	'
Shares, Forfeited	-70	'
Shares, Unvested ending balance	807	877
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]	'	'
Weighted average grant date fair value, Unvested beginning balance	$1.81	'
Weighted average grant date fair value, Awarded	$1.97	'
Weighted average grant date fair value, Vested	$1.84	'
Weighted average grant date fair value, Forfeited	$1.65	'
Weighted average grant date fair value, Unvested ending balance	$1.88	$1.81
Weighted average remaining recognition period (in years), Unvested beginning balance	'2 years 3 months 18 days	'1 year 5 months 27 days
Weighted average remaining recognition period (in years), Unvested ending balance	'2 years 3 months 18 days	'1 year 5 months 27 days

Stock_Benefit_Plans_and_StockB5

Stock Benefit Plans and Stock-Based Compensation - Summary Common Stock Reserved for Future Issuance (Detail)	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Common stock reserved for future issuance	12,377,000
Stock options outstanding [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Common stock reserved for future issuance	7,810,000
Awards outstanding [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Common stock reserved for future issuance	807,000
Warrants outstanding [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Common stock reserved for future issuance	594,000
Authorized for future grant under 2005 Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Common stock reserved for future issuance	3,166,000

Income_Taxes_Components_of_Pre

Income Taxes - Components of Pretax Loss from Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
U.S. Domestic	($9,264)	($3,310)	($14,400)
Foreign	-69,784	-13,308	-12,288
Pretax loss from operations	($79,048)	($16,618)	($26,688)

Income_Taxes_Components_of_Ben

Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	($21)	$107	$4
State	186	24	222
Foreign	2,525	2,083	-388
Total current provision (benefit)	2,690	2,214	-162
Deferred:	'	'	'
Federal	229	137	163
State	15	29	8
Foreign	245	-3,539	-4,516
Total deferred provision (benefit)	489	-3,373	-4,345
Total provision (benefit)	$3,179	($1,159)	($4,507)

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal statutory rate	-35.00%	-35.00%	-35.00%
Adjustments for tax effects of:	'	'	'
State taxes, net	-0.10%	0.00%	-0.70%
Stock-based compensation	0.50%	-0.50%	1.80%
Foreign taxes	1.10%	-0.10%	3.60%
Tax credits	-0.40%	-0.70%	-1.20%
Deemed foreign dividend	0.00%	0.20%	10.30%
Intercompany debt forgiveness and other permanent adjustments	9.50%	5.00%	0.80%
Tax rate adjustment	0.20%	0.70%	-0.50%
Uncertain tax positions	2.70%	14.90%	-1.50%
Other	-0.40%	3.30%	-3.10%
Valuation allowance	25.90%	5.20%	8.70%
Effective income tax rate	4.00%	-7.00%	-16.80%

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Allowances and reserves	$816	$1,088
Accrued expenses	3,685	648
Inventory reserves	7,549	7,839
Net operating loss carryforwards	26,497	28,786
Property and equipment	1,171	0
Stock-based compensation	2,769	1,866
Legal settlement	17,998	4,156
Income tax credit carryforwards	1,800	1,276
Total deferred tax assets	62,285	45,659
Valuation allowance	-56,690	-36,031
Total deferred tax assets, net of valuation allowance	5,595	9,628
Deferred tax liabilities:	'	'
Property and equipment	0	926
Intangible assets	4,806	6,910
Goodwill	1,256	1,011
Total deferred tax liabilities	6,062	8,847
Net deferred tax assets (liabilities)	($467)	$781

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax [Line Items]	'	'	'	'
Deferred tax asset, valuation allowance	$56,690,000	$36,031,000	'	'
Number of Years Cumulative Pre-tax Loss	'3 years	'	'	'
Deferred tax assets and recognized tax benefit	'	1,400,000	'	'
Unrecognized tax benefits	7,835,000	5,897,000	4,197,000	4,421,000
Uncertain tax benefits that, if realized, would affect the effective tax rate	7,200,000	'	'	'
Year under income tax examination	'2011	'	'	'
Accrued interest and penalties	1,300,000	'	'	'
Operating loss carryforwards state	39,800,000	'	'	'
Operating loss carryforwards federal	52,900,000	'	'	'
Federal and state net operating loss carryforwards, expiring year	'2033	'	'	'
Federal research and development tax credits	2,700,000	'	'	'
State research and development tax credits	2,300,000	'	'	'
Operating loss carryforwards foreign	$41,000,000	'	'	'
Foreign net operating loss carryforward expire in year	'2018	'	'	'
Federal research and development tax credits [Member]	'	'	'	'
Income Tax [Line Items]	'	'	'	'
Federal research and development tax credits expiration year	'2033	'	'	'

Income_Taxes_Summary_of_Change

Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Unrecognized tax benefits, Beginning Balance	$5,897	$4,197	$4,421
Additions based on tax positions related to the prior year	221	987	73
Additions based on tax positions related to the current year	1,664	743	399
Reductions as a result of positions taken	'	'	-59
Reductions as a result of lapse of applicable statute of limitations	-20	-58	-649
Additions as a result of foreign exchange rates and other	73	28	12
Unrecognized tax benefits, Ending Balance	$7,835	$5,897	$4,197

Segment_and_Geographical_Infor2

Segment and Geographical Information - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
									Location	Location	Location
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of reportable business segment	'	'	'	'	'	'	'	'	1	'	'
Number of geographic regions	'	'	'	'	'	'	'	'	2	2	2
Revenue	$53,065	$50,196	$51,020	$50,443	$52,743	$46,839	$48,235	$48,461	$204,724	$196,278	$197,711
Maximum percentage of revenues	'	'	'	'	'	'	'	'	'	10.00%	10.00%
Minimum percentage of revenues	'	'	'	'	'	'	'	'	10.00%	'	'
Japan [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	$28,000	$28,600	$23,900
Maximum percentage of revenues	'	'	'	'	'	'	'	'	10.00%	'	'
Minimum percentage of revenues	'	'	'	'	'	'	'	'	'	10.00%	10.00%

Segment_and_Geographical_Infor3

Segment and Geographical Information - Schedule of Revenues Attributed to Geographic Location (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total consolidated revenues	$53,065	$50,196	$51,020	$50,443	$52,743	$46,839	$48,235	$48,461	$204,724	$196,278	$197,711
UNITED STATES	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total consolidated revenues	'	'	'	'	'	'	'	'	134,951	130,476	133,824
International [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total consolidated revenues	'	'	'	'	'	'	'	'	$69,773	$65,802	$63,887

Segment_and_Geographical_Infor4

Segment and Geographical Information - Schedule of Long Lived Assets by Geographical Areas (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	$365,630	$382,127
UNITED STATES	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	196,383	213,912
International [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	$169,247	$168,215

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Millions, unless otherwise specified
Related Party Transaction [Line Items]	'	'	'
Indemnification obligations	$1.70	$2.60	'
Healthpoint Capital [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Payable liability	$0.20	$0.20	$0.10

Retirement_Plan_Additional_Inf

Retirement Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Matching contributions by employer	4.00%	'	'
Employer matching contribution, vesting period	'1 year	'	'
Section 401(k) plan [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Total contributions	$0.60	$0.50	$0.50

Restructuring_Activities_Addit

Restructuring Activities - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Sep. 16, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]	'	'	'	'
Restructuring expected cost	$12,000,000	'	'	'
Restructuring expenses	'	9,665,000	0	1,050,000
Restructuring accrual	'	9,170,000	'	'
Additional inventory reserve recorded	'	4,900,000	'	'
Facility Closing [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Restructuring expected cost	'	2,200,000	'	'
Employee Severance [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Restructuring expected cost	'	$9,700,000	'	'

Restructuring_Activities_Restr

Restructuring Activities Restructuring Activities - Movement of Restructuring Reserve (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring expenses	$9,665	$0	$1,050
Restructuring, paid and Other	-495	'	'
Restructuring accrual	9,170	'	'
Restructuring. total costs	11,867	'	'
Restructuring, remaining costs	2,697	'	'
Social Plan [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring expenses	8,893	'	'
Restructuring, paid and Other	-84	'	'
Restructuring accrual	8,809	'	'
Restructuring. total costs	9,705	'	'
Restructuring, remaining costs	535	'	'
French Non-social Plan Costs [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring expenses	210	'	'
Restructuring, paid and Other	-210	'	'
Restructuring accrual	0	'	'
Restructuring. total costs	2,162	'	'
Restructuring, remaining costs	2,162	'	'
US Booked Social Cost [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring expenses	361	'	'
Restructuring, paid and Other	0	'	'
Restructuring accrual	361	'	'
Restructuring. total costs	0	'	'
Restructuring, remaining costs	0	'	'
US Costs Other [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring expenses	201	'	'
Restructuring, paid and Other	-201	'	'
Restructuring accrual	0	'	'
Restructuring. total costs	0	'	'
Restructuring, remaining costs	$0	'	'

Cross_Medical_Additional_Infor

Cross Medical - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Aug. 02, 2012	Jan. 31, 2012	Dec. 31, 2013
	Installment
Guarantees And Letters Of Credit [Line Items]	'	'	'
Initial payment towards settlement	'	$5	'
Number of quarterly payments	13	'	'
Cash obligations	'	'	7
Cash obligations 2014	'	'	4
Cash obligations 2015	'	'	3
Thirteen quarterly payments [Member]	'	'	'
Guarantees And Letters Of Credit [Line Items]	'	'	'
Initial payment towards settlement	1	'	'

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2012		Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'		'		'		'		'		'		'		'		'	'	'
Revenue	$53,065		$50,196		$51,020		$50,443		$52,743		$46,839		$48,235		$48,461		$204,724	$196,278	$197,711
Gross profit	35,255		24,232		32,093		32,742		32,120		29,633		30,196		31,819		124,322	123,768	116,930
Total operating expenses	91,257		37,406		34,992		34,100		36,108		31,606		33,947		31,944		197,755	133,605	141,446
Net loss	($60,407)		($14,510)		($4,661)		($2,649)		($5,355)		($2,469)		($6,374)		($1,261)		($82,227)	($15,459)	($22,181)
Basic and diluted net loss per share (in dollars per share)	($0.62)	[1]	($0.15)	[1]	($0.05)	[1]	($0.03)	[1]	($0.06)	[1]	($0.03)	[1]	($0.07)	[1]	($0.01)	[1]	($0.85)	($0.17)	($0.25)
[1]	Basic and diluted net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal the total for the year.

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Jun. 07, 2012	Mar. 31, 2012	Dec. 31, 2013	Mar. 15, 2014	Mar. 15, 2014	Mar. 15, 2014	Mar. 15, 2014	Mar. 19, 2014	Mar. 17, 2014	Mar. 17, 2014	Mar. 15, 2014
			Orthotec LLC, Litigation Settlement [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Deerfield [Member]	Deerfield [Member]	Maximum [Member]	Healthpoint Capital [Member]
				Orthotec LLC, Litigation Settlement [Member]	By March 31, 2014 [Member]	By April 11, 2014 [Member]	Beginning Fourth Quarter of 2014 [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Deerfield [Member]	Subsequent Event [Member]
					Orthotec LLC, Litigation Settlement [Member]	Orthotec LLC, Litigation Settlement [Member]	Orthotec LLC, Litigation Settlement [Member]			Subsequent Event [Member]	Orthotec LLC, Litigation Settlement [Member]
							Installment
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Litigation settlement, amount	'	'	'	$49,000,000	$1,750,000	$15,750,000	$31,500,000	'	'	'	'
Length of period after closing a financing for the Company to make additional settlement payment	'	'	'	'	'	'25 days	'	'	'	'	'
Litigation settlement, number of quarterly installments	'	'	'	'	'	'	28	'	'	'	'
Litigation settlement, quarterly installments, amount	'	'	'	'	'	'	1,100,000	'	'	'	'
Litigation settlement, contribution by entity involved	'	'	'	'	'	'	'	'	'	'	5,000,000
Litigation settlement interest rate	'	'	'	'	'	'	7.00%	'	'	'	'
Litigation settlement interest, quarterly installments, amount	'	'	'	'	'	'	1,100,000	'	'	'	'
Litigation settlement accrual	'	'	46,200,000	'	'	'	'	'	'	'	'
Maximum borrowing capacity	50,000,000	'	'	'	'	'	'	'	50,000,000	'	'
Aggregate amount of draw down for working capital	'	'	'	'	'	'	'	'	15,000,000	'	'
Increment amount of draw down for general corporate purposes	'	'	'	'	'	'	'	'	2,500,000	'	'
Transaction fee as percentage of principal amount	'	'	'	'	'	'	'	'	2.50%	'	'
Facility agreement stated interest rate	'	'	'	'	'	'	'	'	8.75%	'	'
Purchase of common stock shares for issuance of warrants	'	500,000	'	'	'	'	'	'	6,250,000	'	'
Exercise price of warrants	'	2.5	'	'	'	'	'	1.39	1.39	'	'
Number of common stock called by warrants or rights associated with each disbursement borrowing	'	'	'	'	'	'	'	'	'	10,000,000	'
Number of days following borrowing request to determine exercise price associated with each disbursement borrowing under Facility Agreement	'	'	'	'	'	'	'	'	'15 days	'	'
Net proceeds from initial draw under Facility Agreement	'	'	'	'	'	'	'	$19,500,000	'	'	'
Number of warrants issued	'	'	'	'	'	'	'	4,000,000	'	'	'

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Allowance for Doubtful Accounts [Member]	'		'		'
Movement in Valuation Allowances and Reserves [Roll Forward]	'		'		'
Balance Beginning	$1,074	[1]	$1,055	[1]	$1,154	[1]
Provision	404	[1]	859	[1]	1,094	[1]
Write-offs and recoveries, net	-430	[1]	-840	[1]	-1,193	[1]
Balance Ending	1,048	[1]	1,074	[1]	1,055	[1]
Reserve for Excess and Obsolete Inventories [Member]	'		'		'
Movement in Valuation Allowances and Reserves [Roll Forward]	'		'		'
Balance Beginning	17,222	[2]	13,174	[2]	11,030	[2]
Provision	11,652	[2]	6,658	[2]	4,564	[2]
Write-offs and recoveries, net	-4,928	[2]	-2,610	[2]	-2,420	[2]
Balance Ending	$23,946	[2]	$17,222	[2]	$13,174	[2]
[1]	The provision is included in selling expenses.
[2]	The provision is included in cost of revenues.